+

WO1992013871A1 - Polypeptides et polynucleotides utiles pour le diagnostic et le traitement de neisseria pathogene - Google Patents

Polypeptides et polynucleotides utiles pour le diagnostic et le traitement de neisseria pathogene Download PDF

Info

Publication number
WO1992013871A1
WO1992013871A1 PCT/US1992/000863 US9200863W WO9213871A1 WO 1992013871 A1 WO1992013871 A1 WO 1992013871A1 US 9200863 W US9200863 W US 9200863W WO 9213871 A1 WO9213871 A1 WO 9213871A1
Authority
WO
WIPO (PCT)
Prior art keywords
pilc
polypeptide
neisseria
sequence
encoded
Prior art date
Application number
PCT/US1992/000863
Other languages
English (en)
Inventor
Staffan Normark
Ann-Beth Jonsson
Original Assignee
Washington University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University filed Critical Washington University
Publication of WO1992013871A1 publication Critical patent/WO1992013871A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the invention relates to materials and methodologies for managing the spread of infections caused by microorganisms having type 4 pilin, for example, Neisseria. More specifically, it relates to polypeptides and antibodies useful in vaccines for the treatment of pathologic infections caused by these microorganisms. It also relates to polynucleotides useful for the recombinant production of these polypeptides. In addition, it- relates to polypeptides, antibodies, and polynucleotides used for the detection o these strains.
  • Type 4 pilins are expressed by several bacterial genuses, including Neisseria, Moraxella, Bacteroides, and Pseudomonas . Species within these genuses which have pathogenic members that express type pilins are, for example, N. gonorrhoeae , N. meningitidis , M. bovis, B. nodosns, and P. aeruginosa. In addition, the Tcp pilin of V. cholerae is highly homologous to th type 4 pilins of other genuses. The only known reservoir of the neisseriae is man.
  • the genus includes two gram-negative species of pyogenic cocci that are pathogenic for man: the meningococcus ⁇ JMeisseria meningitidis) and the gonococcus (Neisseria gonorrheae) .
  • Meningitidis causes a variety of infections, most notably, meningitis and bacteremia. Meningococci can be divided into serologic groups on the basis of agglutination reactions with immune serum. The present classification includes groups A through Z. Clinically significant new groups encompass Y and W 135. The major groups are remarkably heterogeneous, but subclassi- fication with additional serologic markers has been possible. Noncapsular antigens have provided the basis for dividing strains of groups into distinct types.
  • Gonorrhea which is caused by N. gonorrhea, is an infection of columnar and transitional epithelium.
  • This disease is the most common reportable communicable disease in the United States, and also has world-wide prevalence. Although treatment of disease caused by gonococci and meningococci are often treated with antibiotics, these microorganisms often develop antibiotic resistance. Thus, prevention with vaccines is a preferable mode to contain the spread of infection. However, for a variety of reasons, including antigenic variation, the development of vaccines has been greatly hampered. For example, a vaccine which prevents gonorrhea is still lacking. In addition, although 56% of the causes of meningococcal disease are caused by serogroup B, an effective vaccine against this serogroup is also lacking.
  • N. gonorrheae and N. meningitidis are organisms completely adapted to the human host, having no other ecological niche. They have acquired a large arsenal of strategies to overcome the human host defense system.
  • the first step in infection with pathological forms of these Neisseria is adherence to target cells. It is thought that the pili of these microorganisms are a major virulence factor. For example, it is known that in the case of N. gonorrheae, piliated (P + ) variants attach much better to susceptible cells than non-piliated (P-) variants (Swanson, 1973; Pearce and Buchanan, 1978) . Moreover, P+ variants, unlike P- variants, are able to establish an infection in human volunteers ( ellog et al, 1968) .
  • pilus protein elicits an immune response, so many antigenic variants exist and continue to develop that vaccines against the pilus protein are not highly effective.
  • Pilin is the major subunit of the pilus. Expression of pilin is controlled at the pilE locus. Brief Description of the Invention
  • PilC pathogenic forms of Neisseria
  • Portions of the DNA sequences of the pilC genes are useful as probes to diagnose the presence of the relevant Neisseria in samples. These DNAs also make available polypeptide sequences of immunoreactive epitopes encoded within the loci, thus permitting the production of polypeptides which are useful as standards or reagents in diagnostic tests and/or as components of vaccines for microorganisms with type 4 pilin and containing one or more epitopes that are immunologically identifiable with an epitope encoded in pilC of Neisseria. Antibodies, both monoclonal and purified polyclonal, directed against PilC epitopes are also useful for diagnostic tests and as therapeutic agents for passive immunization. In addition, by utilizing probes derived from the DNA sequences, it is possible to isolate and sequence portions of the pilC loci from species and strains of interest.
  • one embodiment of the invention is a recombinant polynucleotide encoding a polypeptide comprised of an immunoreactive epitope of a protein encoded in pilC of Neisseria.
  • Another embodiment of the invention is a recombinant expression system comprising a polynucleotide encoding a polypeptide comprised of an immunoreactive epitope of a protein encoded in pile of Neisseria, wherein the polynucleotide is operably linked to a control sequence compatible with a desired host.
  • Yet another embodiment of the invention is purified polypeptide comprised of an immunoreactive epitope of a protein encoded in pilC of Neisseria.
  • Another embodiment of the invention is a recombinant polypeptide comprised of an immunoreactive epitope of a protein encoded in pilC of Neisseria.
  • Still another embodiment of the invention is a vaccine composition for the treatment of Neisseria infection, comprised of a pharmaceutically acceptable excipient and of an effective amount of a recombinant polypeptide, wherein the polypeptide is comprised of an immunoreactive epitope of a protein encoded in pilC of Neisseria.
  • Yet another embodiment of the invention is a composition comprised of purified polyclonal anti-PilC antibodies, wherein the PilC is of Neisseria.
  • An additional embodiment of the invention is a composition comprised of a monoclonal antibody directed against an immunoreactive epitope encoded in pilC of Neisseria.
  • Another embodiment of the invention is a method for producing antibodies to PilC of Neisseria comprising administering to an individual a composition comprised of an isolated immunogenic polypeptide containing a PilC epitope in an amount sufficient to produce an immune response.
  • Yet another embodiment of the invention is an oligomer capable of hybridizing to a sequence in pilC of Neisseria, wherein the oligomer is comprised of a pilC sequence complementary to at least about 6 contiguous nucleotides of pilC.
  • Still another embodiment of the invention is a process for detecting a pilC sequence in an analyte strand, wherein the pilC sequence comprises a selected target region, the process comprising:
  • oligomer capable of hybridizing to the target pilC sequence, wherein the oligomer is comprised of a pilC targeting sequence complementary to at least about 6 contiguous nucleotides of pilC;
  • Yet another embodiment of the invention is a recombinant polynucleotide comprising a DNA sequence of at least 8 contiguous nucleotides from pilC, wherein the pilC sequence is selected from the group of sequences shown in Figure 3, Figure 6, and Figure 7.
  • Another embodiment of the invention is a method of treating an individual for a Neisseria infection comprising administering to the individual antibodies produced according to claim 31, wherein the antibodies are administered in an amount effective to prevent the pathology of the infection.
  • Figure 1 is a genetic and physical map of pilC locus 1, showing the restriction enzyme sites.
  • Figure 2 shows the nucleotide sequence and the deduced amino acid sequence of the 5' -end of pilCl .
  • Figure 3 shows the nucleotide sequence of the sense strand of the pilCl gene.
  • Figure 4 shows the shows the nucleotide sequence of the sense strand of the pilCl gene and the amino acids encoded therein.
  • Figure 5 shows the nucleotide sequence of the sense strand of the pilCl gene, and the effect of frame shift on the putative gene products encoded therein.
  • Figure 6 shows the nucleotide sequences of PCR amplified fragments demonstrating a variation in the length of the G tract and sequence differences in the 5' region of the pilC genes.
  • Figure 7 shows the DNA sequence of the 3' -end of the pilC2 fragment.
  • Figure 8 shows the pilC2 fragment sequence, and the putative amino acids encoded therein.
  • Figure 9 shows a comparison of the analogous portions of pilC2 (top) and pilCl (bottom) DNA sequences, and the putative amino acids encoded therein.
  • the present invention provides polypeptides, antibodies, and polynucleotides which are useful for the detection and treatment of pathogenic microorganisms having type 4 pilin, for example, Neisseria, Moraxella, Bacteroides , and Pseudomonas.
  • N. gonorrheae N. gonorrheae.
  • this gene sequence we have cloned a fragment of the pi!2 gene.
  • polynucleotide probes derived from isolated pilCl and PCR amplification we have detected two possible variants of a pilC gene in N. meningitidis.
  • the sequences of pilC reported herein appear to be novel, in that there are no reported counterparts in Genbank, and no significant homologies were found with any available sequences in that data base.
  • the useful materials and processes of the present invention are made possible by the provision of the sequences of the pilC genes from N. gonorrheae and from N. meningitidis .
  • Information present in the sequences of the pilC genes allows for the design of polypeptides which may be useful as vaccines for treatment of pathogenic Neisseria, as diagnostic tools for the detection of these microorganisms, and as agents for the preparation of antibodies to PilC.
  • this information allows for the design of polynucleotides for the recombinant production of the polypeptides derived from PilC, and for the design of oligomers which are useful as probes and primers for the detection and amplification of target regions of pilC.
  • a polynucleotide "derived from” a designated sequence refers to a polynucleotide sequence which is comprised of a sequence of approximately at least about 6 nucleotides, preferably at least about 8 nucleotides, more preferably at least about 10-12 nucleotides, and even more preferably at least about
  • nucleotides corresponding to a region of the designated nucleotide sequence 15-20 nucleotides corresponding to a region of the designated nucleotide sequence. "Corresponding” means homologous to or complementary to the designated sequence. Regions from which typical polynucleotide sequences may be “derived” include but are not limited to, for example, regions encoding specific epitopes, as well as non-transcribed and/or non- ranslated regions.
  • the derived polynucleotide is not necessarily physically derived from the nucleotide sequence shown, but may be generated in any manner, including for example, chemical synthesis or DNA replication or reverse transcription or transcription. In addition, combinations of regions corresponding to that of the designated sequence may be modified in ways known in the art to be consistent with an intended use.
  • nucleic acid sequence refers to a polypeptide having an amino acid sequence identical to that of a polypeptide encoded in the sequence, or a portion thereof wherein the portion consists of at least
  • This terminology also includes a polypeptide expressed from a designated nucleic acid sequence.
  • a recombinant or derived polypeptide is not necessarily translated from a designated nucleic acid sequence. It may be generated in any manner, including for example, chemical synthesis, or expression of a recombinant expression system, or isolation from a microorganism.
  • a recombinant or derived polypeptide may include one or more analogs of amino acids or unnatural amino acids in its sequence. Methods of inserting analogs of amino acids into a sequence are known in the art. It also may include one or more labels, which are known to those of skill in the art.
  • polynucleotide intends a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation: (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide other than that to which it is linked in nature, (3) does not occur in nature, or (4) is not in the form of a library.
  • polynucleotide refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, this term includes double- and single-stranded DNA and RNA.
  • modifications for example, labels which are known in the art, methylation, "caps", substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), those containing pendant moieties, such as, for example proteins (including for e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators
  • purified polynucleotide refers to a polynucleotide which is essentially free, i.e., contains less than about 50%, preferably less than about 70%, and even more preferably less than about 90% of polypeptides with which the polynucleotide is naturally associated.
  • Techniques for purifying polynucleotides from bacteria include for example, disruption of the bacteria with a chaotropic agent, differential extraction and separation of the polynucleotide(s) and polypeptides by ion-exchange chromatography, affinity chromatography, and sedimentation according to density.
  • purified polypeptide refers to a polypeptide or fragment thereof which is essentially free, i.e., contains less than about 50%, preferably less than about 70%, and even more preferably less than about
  • cells denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities refer to cells which can be, or have been, used as recipients for recombinant vector or other transfer DNA, and include the progeny of the original cell which has been transfected.
  • progeny of a single parental cell may not necessarily be completely identical in orphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.
  • a “replicon” is any genetic element, e.g., a plasmid, a chromosome, a virus, a cosmid, etc. that behaves as an autonomous unit of polynucleotide replica ⁇ tion within a cell; i.e., capable of replication under its own control.
  • a “vector” is a replicon in which another polynucleotide segment is attached, so as to bring about the replication and/or expression of the attached segment.
  • Control sequence refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and terminators; in eukaryotes, generally, such control sequences include promoters, terminators and, in some instances, enhancers.
  • control sequences is intended to include, at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences.
  • Operaably linked refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.
  • a control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
  • ORF "open reading frame” is a region of a polynucleotide sequence which encodes a polypeptide; this region may represent a portion of a coding sequence or a total coding sequence.
  • a "coding sequence” is a polynucleotide sequence which is transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5' -terminus and a translation stop codon at the 3'-terminus.
  • a coding sequence can include, but is not limited to mRNA, cDNA, and recombinant polynucleotide sequences.
  • Immunologically identifiable with/as refers to the presence of epitope(s) and polypeptides(s) which are also present in the designated polypeptide(s) . Immunological identity may be determined by antibody binding and/or competition in binding; these techniques are known to those of average skill in the art, and are also illustrated infra.
  • epitope refers to an antigenic determinant of a polypeptide.
  • An epitope could comprise 3 amino acids in a spatial conformation which is unique to the epitope. Generally an epitope consists of at least 5 such amino acids, and more usually, consists of at least 8-10 such amino acids.
  • Methods of determining the spatial conformation of amino acids are known in the art, and include, for example, x-ray crystallography and 2-dimensional nuclear magnetic resonance.
  • a polypeptide is "immunoreactive" when it is “immunologically reactive” with an antibody, i.e., when it binds to an antibody due to antibody recognition of a specific epitope contained within the polypeptide.
  • Immunological reactivity may be determined by antibody binding, more particularly by the kinetics of antibody binding, and/or by competition in binding using as competitor(s) a known polypeptide(s) containing an epitope against which the antibody is directed.
  • the techniques for determining whether a polypeptide is immunologically reactive with an antibody are known in the art.
  • An "immunoreactive" polypeptide may also be “immunogenic”.
  • the term "immunogenic polypeptide” is a polypeptide that elicits a cellular and/or humoral immune response, whether alone or linked to a carrier in the presence or absence of an adjuvant.
  • an antibody refers to a polypeptide or group of polypeptides which are comprised of at least one antibody combining site.
  • An “antibody combining site” or “binding domain” is formed from the folding of variable domains of an antibody molecule(s) to form three-dimensional binding spaces with an internal surface shape and charge distribution complementary to the features of an epitope of an antigen, which allows an immunological reaction with the antigen.
  • An antibody combining site may be formed from a heavy and/or a light chain domain (VH and VL, respectively) , which form hypervariable loops which contribute to antigen binding.
  • the term “antibody” includes, for example, vertebrate antibodies, hybrid antibodies, chimeric antibodies, altered antibodies, univalent antibodies, the Fab proteins, and single domain antibodies.
  • a "single domain antibody” is an antibody which is comprised of an VH domain, which reacts immunologically with a designated antigen.
  • a dAB does not contain a VL domain, but may contain other antigen binding domains known to exist in antibodies, for example, the kappa and lambda domains. Methods for preparing dABs are known in the art. See, for example,
  • Antibodies may also be comprised of VH and VL domains, as well as other known antigen binding domains.
  • vertebrate antibodies refers to antibodies which are tetramers or aggregates thereof, comprising light and heavy chains which are usually aggregated in a "Y" configuration and which may or may not have covalent linkages between the chains.
  • the amino acid sequences of all the chains of a particular antibody are homologous with the chains found in one antibody produced by the lymphocyte which produces that antibody in situ, or in vitro (for example, in hybridomas) .
  • Vertebrate antibodies typically include native antibodies, for example, purified polyclonal antibodies and monoclonal antibodies. Examples of the methods for the preparation of these antibodies are described infra.
  • Hybrid antibodies are antibodies wherein one pair of heavy and light chains is homologous to those in a first antibody, while the other pair of heavy and light chains is homologous to those in a different second anti- body. Typically, each of these two pairs will bind different epitopes, particularly on different antigens.
  • hybrids may also be formed using chimeric chains, as set forth below.
  • Chimeric antibodies are antibodies in which the heavy and/or light chains are fusion proteins.
  • the constant domain of the chains is from one particular species and/or class, and the variable domains are from a different species and/or class.
  • altered antibodies refers to antibodies in which the naturally occurring amino acid sequence in a vertebrate antibody has been varied. Utilizing recombinant DNA techniques, antibodies can be redesigned to obtain desired characteristics. The possible variations are many, and range from the changing of one or more amino acids to the complete redesign of a region, for example, the constant region. Changes in the constant region, in general, to attain desired cellular process characteristics, e.g., changes in complement fixation, interaction with membranes, and other effector functions. Changes in the variable region may be made to alter antigen binding characteristics.
  • the antibody may also be engineered to aid the specific delivery of a molecule or substance to a specific cell or tissue site.
  • the desired alterations may be made by known techniques in molecular biology, e.g., recombinant techniques, site directed mutagenesis, etc.
  • immunovalent antibodies which are aggregates comprised of a heavy chain/light chain dimer bound to the Fc (i.e., constant) region of a second heavy chain. This type of antibody escapes antigenic modulation. See, e.g., Glennie et al. (1982). Included also within the definition of antibod ⁇ ies are "Fab" fragments of antibodies.
  • the “Fab” region refers to those portions of the heavy and light chains which are roughly equivalent, or analogous, to the sequences which comprise the branch portion of the heavy and light chains, and which have been shown to exhibit immunological binding to a specified antigen, but which lack the effector Fc portion .
  • “Fab” includes aggregates of one heavy and one light chain (commonly known as Fab 7 ), as well as tetramers containing the 2H and 2L chains (referred to as F(ab) 2 ), which are capable of selectively reacting with a designated antigen or antigen family.
  • Fab antibodies may be- divided into subsets analogous to those described above, i.e, “vertebrate Fab", “hybrid Fab”, “chimeric Fab”, and “altered Fab”.
  • Methods of producing “Fab” fragments of antibodies are known within the art and include, for example, proteolysis, and synthesis by recombinant techniques.
  • polypeptide refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.
  • Transformation refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, for example, direct uptake, transduction, f-mating or electroporation.
  • the exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host genome.
  • Treatment refers to prophylaxis and/or therapy.
  • Immunogenic is meant an agent used to stimulate the immune system of a living organism, so that one or more functions of the immune system are increased and directed towards the immunogenic agent.
  • Immunogenic agents include vaccines. Immunogenic agents can be used in the production of antibodies, both isolated polyclonal antibodies and monoclonal antibodies, using techniques known in the art.
  • Immunization refers to the process of inducing an increased level of antibodies and/or cellular immune response in which T-lymphocytes respond by killing the pathogen and/or activate other cells involved in the immune response pathway.
  • the antibodies produced as a result of immunization may belong to any of the immunological classes, such as immunoglobulins A, D, E, G or M.
  • mammals refers to vertebrates, particularly members of the mammalian species, and includes but is not limited to domestic animals, sports animals, and primates, including humans.
  • the "sense strand" of a nucleic acid contains the sequence that has sequence homology to that of mRNA.
  • the "anti-sense strand” contains a sequence which is complementary to that of the “sense strand”.
  • probe refers to a polynucleotide which forms a hybrid structure with a sequence in a target region, due to complementarity of at least one sequence in the probe with a sequence in the target region.
  • the polynucleotide regions of probes may be composed of DNA, and/or RNA, and/or synthetic nucleotide analogs.
  • target region refers to a region of the nucleic acid which is to be amplified and/or detected.
  • target sequence refers to a sequence with which a probe or primer will form a stable hybrid under desired conditions.
  • primer refers to an oligomer which is capable of acting as a point of initiation of synthesis of a polynucleotide strand when placed under appropriate conditions.
  • the primer will be completely or substantially complementary to a region of the polynucleotide strand to be copied. Thus, under conditions conducive to hybridization, the primer will anneal to the complementary region of the analyte strand.
  • the primer Upon addition of suitable reactants, (e.g., a polymerase, nucleotide triphosphates, and the like) , the primer is extended by the polymerizing agent to form a copy of the analyte strand.
  • suitable reactants e.g., a polymerase, nucleotide triphosphates, and the like.
  • the primer may be single-stranded, or alternatively may be partially or fully double-stranded.
  • analyte polynucleotide and “analyte strand” refer to a single- or double-stranded nucleic acid molecule which is suspected of containing a target sequence, and which may be present in a biological sample.
  • a "biological sample” refers to a sample of tissue or fluid isolated from an individual, including but not limited to, for example, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, tumors, organs, and also samples of in vitro cell culture constituents (including but not limited to conditioned medium resulting from the growth of cells in cell culture medium, putatively virally infected cells, recombinant cells, and cell components) .
  • the term “oligomer” refers to primers and to probes. The term oligomer does not connote the size of the molecule.
  • typically oligomers are no greater than 1000 nucleotides, more typically are no greater than 500 nucleotides, even more typically are no greater than 250 nucleotides; they may be no greater than 100 nucleotides, and may be no greater than 75 nucleotides, and also may be no greater than 50 nucleotides in length.
  • Coupled refers to attachment by covalent bonds or by strong non-covalent interactions (e.g., hydrophobic interactions, hydrogen bonds, etc.). Covalent bonds may be, for example, ester, ether, phosphoester, amide, peptide, imide, carbon-sulfur bonds, carbon-phosphorus bonds, and the like.
  • support refers to any solid or semi- solid surface to which a desired polypeptide or polynucleotide may be anchored. Suitable supports include glass, plastic, metal, polymer gels, and the like, and may take the form of beads, wells, dipsticks, membranes, and the like.
  • label refers to any atom or moiety which can be used to provide a detectable (preferably quantifiable) signal, and which can be attached to a polynucleotide or polypeptide.
  • type 4 pilin refers to pilins that contain a conserved amino terminal hydrophobic domain beginning with an amino-terminal phenylalanine that is methylated upon processing and secretion of the pilin. Another characteristic feature of type 4 pilins is that in the propilin form they contain similar six- or seven-amino acid long leader peptides, which are much shorter than typical signal sequences. Type 4 pilins are expressed by several bacterial genuses, including Neisseria, Moraxella, Bacteroides, and Pseudomonas. Species within these genuses which express type 4 pilins are, for example, N. gonorrhoeae, N.
  • type 4 pilin also includes the Tcp pilin of Vibrio, (for example, V. cholerae) , that is highly homologous to the type 4 pilins of other genuses.
  • Tcp pilin contains the characteristic amino-terminal hydrophobic domain as well as having a modified N-terminal amino acid that in this case may be a modified methionine because the Tcp pilin gene encodes a methionine residue at the position where all the others encode a phenylalanine.
  • Precursor TcpA contains a much longer leader sequence than typical type 4 propilins but retains homology in the region surrounding the processing site.
  • n pilC n refers to a gene encoding a polypeptide involved in the assembly of type 4 pilin, which may also be required for attachment of the pilin, and that is comprised of an epitope that is immunologically identifiable with an epitope in PilC of N. gonorrhae or N. meningitidis. Included within this term is any homologous region from Vibrio, tcpC.
  • the term "PilC” refers to a polypeptide encoded within pilC, and includes TcpC of Vibrio.
  • the description of the method to retrieve the DNA sequences is mostly of historical interest.
  • the resultant sequences (and their complements) are provided herein, and the sequences, or any portion thereof, could be prepared using synthetic methods, or by a combination of synthetic methods with retrieval of partial sequences using methods similar to those described herein.
  • the description infra, of "walking" the genome by isolating overlapping DNA sequences from the N. gonorrheae lambda gt-11 library and from an EMBL3 library provides one method by which DNAs corresponding to the pile genomes from, inter alia, N. gonorrheae and N. meningitidis, respectively, may be isolated.
  • TCP pili of Vibrio cholerae has revealed that a number of closely linked genes are required for pilin processing and assembly into a structure (Taylor et al., 1988) .
  • the TCP pilin does not carry an N-methylphenylalanine but its primary sequence is highly homologous to the Type 4 class of pilins.
  • the N. gonorrhoeae pilus facilitates adherence of the bacterium to a number of eukaryotic cell types (Watt et al., 1980) and is thought to play a role in bacterial interaction with neutrophils (Fischer and Rest,
  • the pilin is encoded from one or two pilE loci
  • the PilC protein described herein is a protein encoded within a pilC or equivalent (for example, tcpC) locus or gene.
  • a pilC or equivalent for example, tcpC
  • the PilC protein is expressed in small amounts. It is the only protein that is enriched in highly purified preparations of MS11 pili. PilC was not released from a nonpilated MS11 (P " n) variant using the same procedure suggesting that this protein interacts with the polymerized pilus fiber.
  • Frameshifting in pilCl also occurred in E. coli .
  • two variants with 10 residues were found out of 12 clones sequenced. It may therefore be that there is a selection against in frame variants with 10 Gs in N. gonorrhoeae.
  • a change from five glycines to four in the signal peptide may for example have an effect on the physical properties of the precursor form of PilC such that the signal peptide is not cleaved off.
  • E. coli strain AA10 is recA. Therefore, frameshift mutations in the G tract of pilC occurs independent of the RecA protein.
  • Translational frameshifting has been shown to regulate phase and antigenic variation of the gonococcal opacity protein PII that is encoded by a number of opa loci showing sequence variations.
  • PII gonococcal opacity protein
  • a number of pentameric CTCTT repeats are present in the region encoding the signal peptide (Stern et al. 1986) .
  • Variation in the number of repeats is independent of recA in N. gonorrhoeae as well as in E. coli (Murphy et al., 1989) .
  • variant sequences differing outside the G tract were obtained by PCR amplification of the 5' end of pile from four N. gonorrhoeae strains.
  • the region 5' of the G tract was invariant, as was the 3' end of the amplified region. All variation was confined to a region located 3' of the G tract. At least some of these sequence variations can be explained by mismatch pairing events.
  • the addition of four nucleotides distal to the G tract in variant sequence 4 is possible to explain by a two step mispairing event occurring within variant sequence 2. Slip strand mispairing between the two CA residues in -GGCGCAGGCGCA- would yield -GGCGCAGGCGCAGGCGCA- .
  • a second mispairing event occurring between the two C-residues at positions 3 and 5 gives rise to the sequence -GGCAGGCGCAGGCGCA- present in variant 4. It may therefore be that a sequence close to a poly(G) tract is prone to slipped strand mispairing.
  • Gonococcal pilus phase variation is associated with an altered nucleotide sequence of pilE via recombinations with silent pilS sequences (Haas and
  • PilC expression causes pilus expression to phase vary.
  • Five out of five P " pilin producing descendants from MSll ⁇ (P + , PilC 4" ) that expressed pilin did not express PilC. All tested P + revertants from the five P ⁇ , PilC " variants had regained expression of PilC.
  • a double mutant in pilCl and pilC2 was stably nonpiliated, expressed pilin, but expressed amounts of pilin that did not express any pili when examined by transmission electron microscopy. It is therefore believed that out of frame mutations of both pilCl and pilC2 will abolish pili formation.
  • PilC " variants from MSII mk (P + ,PilC " ) are generated by transformation of pilCl sequences and homologous recombination with pilC2 thus generating variants with two pilCl 5 ' ends at both pilC loci.
  • PilC + revertants from PilC " clones must, however, all be due to frameshift mutations in either pilCl or pilC2.
  • PilC forms an outer membrane pore or assembly center enabling the pilin subunits to be assembled and translocated across the outer membrane analogous to the proposed function of the high molecular weight proteins required for the assembly of enterobacterial pili (the latter of which is discussed in Norgren et al., 1987).
  • PilC may act as an initiator for polymerization. In the latter case PilC would be expected to be located at the tip of the polymerized pilus.
  • immunogenically active polypeptides encoded within pilC are prepared.
  • the availability of pilC DNA sequences, either those isolated by utilizing the DNA sequences described in the Examples, or nucleotide sequences derived therefrom (including segments and modifications of the sequence) permits the construction of expression vectors encoding immunologically reactive regions of the polypeptide encoded in either strand. Immunological reactivity may be determined by immunoassay using antibodies raised to PilC.
  • Fragments encoding the desired polypeptides are derived from the DNA clones using conventional restriction digestion or by synthetic methods, and are ligated into vectors which may, for example, contain portions of fusion sequences such as beta-galactosidase or superoxide dismutase (SOD) , prefer ⁇ ably SOD.
  • fusion sequences such as beta-galactosidase or superoxide dismutase (SOD) , prefer ⁇ ably SOD.
  • any desired portion of the pilC DNA containing an open reading frame, in either sense strand, can be obtained as a recombinant polypeptide, such as a mature or fusion protein; alternatively, a polypeptide encoded in the DNA can be provided by chemical synthesis.
  • the DNA encoding the desired polypeptide, whether in fused or mature form, and whether or not containing a signal sequence to permit secretion, may be ligated into expression vectors suitable for any convenient host. Both eukaryotic and prokaryotic host systems are presently used in forming recombinant polypeptides, and a summary of some of the more common control systems and host cell lines is given infra.
  • polypeptide is then isolated from lysed cells or from the culture medium and purified to the extent needed for its intended use. Purification may be by techniques known in the art, for example, differential extraction, salt fractionation, chromatography on ion exchange resins, affinity chromatography, centrifugation, and the like. See, for example, Methods in Enzymology for a variety of methods for purifying proteins.
  • Such polypeptides can be used as diagnostics, or those which give rise to neutralizing antibodies may be formulated into vaccines. Antibodies raised against these polypeptides can also be used as diagnostics, or for passive immunotherapy.
  • the PilC antigens may also be isolated from meningococci and from gonococci.
  • the bacteria may be grown by conditions known in the art, some of which are described infra.
  • a method for isolating PilC from gonococci is described infra.
  • the immunoreactive polypeptides may be conjugated with carrier.
  • An antigenic region of a polypeptide is gener ⁇ ally relatively small--typically 8 to 10 amino acids or less in length. Fragments of as few as 5 amino acids may characterize an antigenic region. These segments may correspond to regions of PilC antigen. Accordingly, using the DNAs of pilC as a basis, DNAs encoding short segments of PilC polypeptides can be expressed recombinantly either as fusion proteins, or as isolated polypeptides. In addition, short amino acid sequences can be conveniently obtained by chemical synthesis. In instances wherein the synthesized polypeptide is . correctly configured so as to provide the correct epitope, but is too small to be immunogenic, the polypeptide may be linked to a suitable carrier.
  • link ⁇ age A number of techniques for obtaining such link ⁇ age are known in the art, including the formation of disulfide linkages using
  • SMCC 4- (N-maleimido-methyl)cyclohexane-1-carboxylate
  • SMCC 4- (N-maleimido-methyl)cyclohexane-1-carboxylate
  • These reagents create a disulfide linkage between themselves and peptide cysteine residues on one protein and an amide linkage through the epsilon-amino on a lysine, or other free amino group in the other.
  • a variety of such disulfide/amide-forming agents are known. See, for example, Immun. Rev. (1982) ⁇ 2.:185.
  • Other bifunctional coupling agents form a thioether rather than a disulfide linkage. Many of these thio-ether-forming agents are commercially available and include reactive esters of 6-maleimidocaproic acid, 2-bromoacetic acid, 2-iodoacetic acid,
  • Any carrier may be used which does not itself induce the production of antibodies harmful to the host.
  • Suitable carriers are typically large, slowly metabolized macromolecules such as proteins; polysaccharides, such as latex functionalized sepharose, agarose, cellulose, cel ⁇ lulose beads and the like; polymeric amino acids, such as polyglutamic acid, polylysine, and the like; amino acid copolymers; and inactive virus particles or attenuated bacteria of other strains, for example, those of Salmonella.
  • Especially useful protein substrates are serum albumins, keyhole limpet hemocyanin, immunoglobulin molecules, thyroglobulin, ovalbumin, tetanus toxoid, and other proteins well known to those skilled in the art.
  • polypeptides comprising truncated PilC amino acid sequences encoding at least one immunologically reactive epitope are useful immunological reagents.
  • polypeptides comprising such truncated sequences can be used as reagents in an immunoassay.
  • These polypeptides also are candidate subunit antigens in compositions for antiserum production or vaccines. While these truncated sequences can be produced by various known treatments of native bacterial protein, it is generally preferred to make synthetic or recombinant polypeptides comprising a PilC sequence.
  • Polypeptides comprising these truncated PilC sequences can be made up entirely of PilC sequences (one or more epitopes, either contiguous or noncontiguous) , or PilC sequences and heterologous sequences in a fusion protein.
  • Useful heterologous sequences include sequences that provide for secretion from a recombinant host, enhance the immunological reactivity of the PilC epitope(s), or facilitate the coupling of the polypeptide to an immunoassay support or a vaccine carrier. See, e.g., EPO Pub. No. 116,201;
  • the size of polypeptides comprising the truncated PilC sequences can vary widely, the minimum size being a sequence of sufficient size to provide an immunologically reactive PilC epitope, while the maximum size is not critical. For convenience, the maximum size usually is not substantially greater than that required to provide the desired PilC epitopes and function(s) of the heterologous sequence, if any.
  • the truncated PilC amino acid sequence will range from about 5 to about 100 amino acids in length. More typically, however, the PilC sequence will be a maximum of about 50 amino acids in length, preferably a maximum of about 30 amino acids. It is usually desirable to select PilC sequences of at least about 10, 12 or 15 amino acids, up to a maximum of about 20 or 25 amino acids.
  • Truncated PilC amino acid sequences comprising epitopes can be identified in a number of ways.
  • the entire PilC protein sequence can be screened by preparing a series of short peptides that together span the entire protein sequence.
  • lOOmer polypeptides it would be routine to test each polypeptide for the presence of epitope(s) showing a desired reactivity, and then testing progressively smaller and overlapping fragments from an identified lOOmer to map the epitope of interest. Screening such peptides in an immunoassay is within the skill of the art. It is also known to carry out a computer analysis of a protein sequence to identify potential epitopes, and then prepare oligopeptides comprising the identified regions for screening.
  • the immunogenicity of the epitopes of PilC may also be enhanced by preparing them in mammalian or yeast systems fused with or assembled with particle-forming proteins such as, for example, that associated with hepatitis B surface antigen. See, e.g., U.S. Pat. No. 4,722,840. Constructs wherein the PilC epitope is linked directly to the particle-forming protein coding sequences produce hybrids which are immunogenic with respect to the PilC epitope.
  • all of the vectors prepared include epitopes specific to HBV, having various degrees of immunogenicity, such as, for example, the pre-S peptide.
  • particles constructed from particle forming protein which include PilC sequences are immunogenic with respect to the microorganism encoding the PilC epitope (for example, Neisseria, Vibrio, Moraxella, Bacteroides, or Pseudomonas) and HBV.
  • the microorganism encoding the PilC epitope for example, Neisseria, Vibrio, Moraxella, Bacteroides, or Pseudomonas
  • Hepatitis surface antigen has been shown to be formed and assembled into particles in S. cerevisiae (Valenzuela et al. (1982)), as well as in, for example, mammalian cells (Valenzuela, P., et al. (1984)). The formation of such particles has been shown to enhance the immunogenicity of the monomer subunit.
  • the constructs may also include the immunodominant epitope of HBSAg, comprising the 55 amino acids of the presurface (pre-S) region. Neurath et al. (1984) .
  • Constructs of the pre-S-HBSAg particle expressible in yeast are disclosed in EPO 174,444, published March 19, 1986; hybrids including heterologous viral sequences for yeast expression are disclosed in EPO 175,261, published March 26, 1966. These constructs may also be expressed in mammalian cells such as Chinese hamster ovary (CHO) cells using an SV40-dihydrofolate reductase vector (Michelle et al. (1984)).
  • portions of the particle-forming protein coding sequence may be replaced with codons encoding a PilC epitope.
  • regions which are not required to mediate the aggregation of the units to form immunogenic particles in yeast or mammals can be deleted, thus eliminating additional HBV antigenic sites from competition with the PilC epitope.
  • the immunoreactive polypeptides encoded in pilC are prepared into vaccines.
  • Vaccines may be prepared from one or more immunogenic polypeptides derived from pile. If recombinant, these polypeptides may be expressed in various host cells (e.g., bacteria, yeast, insect, or mammalian cells) , or alternatively may be isolated from the bacterial preparations.
  • host cells e.g., bacteria, yeast, insect, or mammalian cells
  • live vaccines of attenuated microorganisms which express one or more recombinant polypeptides derived from the pilC gene. Suitable attenuated microorganisms are known in the art and include, for example, viruses (e.g., vaccinia virus (see Brown et al. (1986)), as well as bacteria.
  • vaccines which contain an immunogenic polypeptide(s) as active ingredients, is known to one skilled in the art.
  • such vaccines are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solu ⁇ tion in, or suspension in, liquid prior to injection may also be prepared.
  • the preparation may also be emulsified, or the protein encapsulated in liposomes.
  • the active immunogenic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient.
  • excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof.
  • the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine.
  • adjuvants which may be effective include but are not limited to: aluminum hydroxide, N-acetyl-muramyl- L-threonyl-D-isoglutamine (thr-MDP) , N-acetyl-nor- muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP) , N-acetylmuramyl-L-alanyl-D-isoglutaminyl-
  • thr-MDP N-acetyl-muramyl- L-threonyl-D-isoglutamine
  • nor-MDP N-acetylmuramyl-L-alanyl-D-isoglutaminyl-
  • MTP-PE L-alanine-2- (1' -2' -dipalmitoyl-sn-glycero-3-hydroxyphosph oryloxy) -ethylamine
  • RIBI L-alanine-2- (1' -2' -dipalmitoyl-sn-glycero-3-hydroxyphosph oryloxy) -ethylamine
  • MTP-PE monophosphoryl lipid A
  • RIBI RIBI
  • the effectiveness of an adjuvant may be determined by measuring the amount of antibodies directed against an immunogenic polypeptide containing a PilC immunoreactive sequence resulting from administration of this polypeptide in vaccines which are also comprised of the various adjuvants.
  • the vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly.
  • Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations.
  • suppositories traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably l%-2%.
  • Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like.
  • compositions take the form of solutions, suspen ⁇ sions, tablets, pills, capsules, sustained release formulations or powders and contain 10%-95% of active ingredient, preferably 25%-70%.
  • the proteins may be formulated into the vaccine as neutral or salt forms.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids such as acetic, oxalic, tartaric, maleic, and the like.
  • Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
  • inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
  • the vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effective.
  • the quantity to be administered which is generally in the range of 5 micrograms to 250 micrograms of antigen per dose, depends on the subject to be treated, capacity of the subject's immune system to synthesize antibodies, and the degree of protection desired. Precise amounts of active ingredient required to be administered may depend on the judgment of the practitioner and may be peculiar to each subject.
  • the vaccine may be given in a single dose schedule, or preferably in a multiple dose schedule.
  • a multiple dose schedule is one in which a primary course of vaccination may be with 1-10 separate doses, followed by other doses given at subsequent time intervals required to maintain and or reenforce the immune response, for example, at 1-4 months for a second dose, and if needed, a subsequent dose(s) after several months.
  • the dosage regimen will also, at least in part, be determined by the need of the individual and be dependent upon the judgment of the practitioner.
  • the vaccine containing the im ⁇ munogenic antigen(s) derived from pilC may be administered in conjunction with other immunoregulatory agents, for example, immune globulins.
  • Another embodiment of the invention are antibodies which react immunologically with PilC epitopes.
  • the immunogenic polypeptides prepared as described above are used to produce antibodies, including polyclonal and monoclonal. If polyclonal antibodies are desired, a selected mammal (e.g., mouse, rabbit, goat, horse, etc.) is immunized with an immunogenic polypeptide bearing a PilC epitope(s) .
  • Serum from the immunized animal is collected and treated according to known procedures. If serum containing polyclonal antibodies to a PilC epitope (i.e., an epitope encoded within pilC) contains antibodies to other antigens, the polyclonal antibodies can be purified by immunoaffinity chromatography. Techniques for producing and processing polyclonal antisera are known in the art, see for example, Mayer and Walker (1987) .
  • Monoclonal antibodies directed against PilC epitopes can also be readily produced by one skilled in the art.
  • the general methodology for making monoclonal antibodies by hybridomas is well known.
  • Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier et al. (1980); Hammerling et al. (1981); Kennett et al. (1980); see also.
  • Panels of monoclonal antibodies produced against PilC epitopes can be screened for various properties; i.e., for isotype, epitope affin ⁇ ity, etc.
  • Antibodies both monoclonal and polyclonal, which are directed against PilC epitopes are particularly useful in diagnosis, and those which are neutralizing are useful in passive immunotherapy. Methods for introducing antibodies into an individual to accomplish passive immunotherapy are known in the art. In addition, monoclonal antibodies, in particular, may be used to raise anti-idiotype antibodies.
  • Anti-idiotype antibodies are immunoglobulins which carry an "internal image" of the antigen of the infectious agent against which protection is desired. See, for example, Nisonoff, A., et al. (1981) and Dreesman et al. (1985) . Techniques for raising anti-idiotype antibodies are known in the art. See, for example, Grzych (1985), MacNamara et al. (1984), and Uytdehaag et al. (1985) .
  • anti-idiotype antibodies may also be useful for treatment, vaccination and/or diagnosis of the relevant microorganism encoding the antigen of interest, (for example, Neisseria, Pseudomonas, Moraxella, Bacteroides , or Vibrio) as well as for an elucidation of the immunogenic regions of PilC.
  • Another embodiment of the invention concerns immunoassays and diagnostic kits.
  • the polypeptides which contain epitopes encoded in pilC which are immunoreactive with anti-PilC antibodies in biological samples are useful in immunoassays to detect presence of anti-PilC antibodies, or the presence of the relevant microorganism or its antigens in biological samples.
  • the immunoassay will utilize a polypeptide comprised of at least one epitope derived from PilC or encoded in pile.
  • the immunoassay uses a combination of epitopes including the one derived from PilC or encoded in pilC. These epitopes may be derived from the same or from different polypeptides, and may be in separate recombinant or natural polypeptides, or together in the same recombinant polypeptides.
  • An immunoassay may use, for example, a monoclonal antibody directed towards an epitope(s), a combination of monoclonal antibodies directed towards epitopes of one antigen, monoclonal antibodies directed towards epitopes of different antigens, polyclonal antibodies directed towards the same antigen, or polyclonal antibodies directed towards different antigens. Protocols may be based, for example, upon competition, or direct reaction, or sandwich type assays. Protocols may also, for example, use solid supports, or may be by immunoprecipitation. Most assays involve the use of labeled antibody or polypeptide; the labels may be, for example, enzymatic, fluorescent, chemiluminescent, radioactive, or dye molecules. Assays which amplify the signals from the probe are also known; examples of which are assays which utilize biotin and avidin, and enzyme-labeled and mediated immunoassays, such as ELISA assays.
  • an immunoassay for an anti-PilC antibody(s) will involve selecting and preparing the test sample suspected of containing the antibodies, such as a biological sample, then incubating it with an immunoreactive (also called antigenic) polypeptide(s) containing at least one epitope encoded in pilC.
  • the incubation is under conditions that allow antigen-antibody complexes to form. Suitable incubation conditions are well known in the art.
  • complexes which are formed which contain the immunoreactive polypeptide are detected.
  • the immunoassay may be, without limitations, in a heterogenous or in a homogeneous format, and of a standard or competitive type.
  • the polypeptide is typically bound to a solid support to facilitate separa ⁇ tion of the sample from the polypeptide after incubation.
  • solid supports that can be used are nitro ⁇ cellulose (e.g., in membrane or microtiter well form), polyvinyl chloride (e.g., in sheets or microtiter wells), polystyrene latex (e.g., in beads or microtiter plates, polyvinylidine fluoride (known as Immulon) , diazotized paper, nylon membranes, activated beads, and Protein A beads.
  • Dynatech Immulonl or Immulon2 microtiter plates or 0.25 inch polystyrene beads can be used in the heterogeneous format.
  • the solid support containing the antigenic polypeptide is typically washed after separating it from the test sample, and prior to detection of bound antibod ⁇ ies. Both standard and competitive formats are known in the art.
  • test sample is incubated with antigen in solution.
  • antigen in solution.
  • it may be under conditions that will precipitate any antigen-antibody complexes which are formed.
  • Both standard and competitive formats for these assays are known in the art.
  • the amount of anti-PilC antibodies forming the antibody-antigen complex is directly monitored. This may be accomplished by determining whether labeled anti-xenogeneic (e.g., anti-human) antibodies which recognize an epitope on anti-PilC antibodies will bind due to complex formation.
  • labeled anti-xenogeneic e.g., anti-human
  • the amount of anti-PilC antibodies in the sample is deduced by monitoring the competitive effect on the binding of a known amount of labeled antibody (or other competing ligand) in the complex.
  • Complexes formed comprising anti-PilC antibody are detected by any of a number of known techniques, depending on the format.
  • unlabeled anti-PilC antibodies in the complex may be detected using a conjugate of antixenogeneic Ig complexed with a label, (e.g., an enzyme label).
  • the test sample which may be a biological sample, is incubated with anti-PilC antibodies under conditions that allow the formation of antigen-antibody complexes.
  • Various formats can be employed. For example, a "sandwich assay" may be employed, where antibody bound to a solid support is incubated with the test sample; washed; incubated with a second, labeled antibody to the analyte, and the support is washed again. Analyte is detected by determining if the second antibody is bound to the support.
  • a test sample is usually incubated with antibody and a labeled, competing antigen is also incubated, either sequentially or simultaneously.
  • the antigenic regions of the polypeptides encoded in pilC can be mapped and identified by screening the antigenicity of expression products of pilC DNAs which encode portions of the PilC.
  • the expression products may be from a variety of expression systems, including, for example bacterial systems, yeast systems, insect systems, and eukaryotic cell systems.
  • studies giving rise to an antigenicity index and hydrophobicity/hydrophilicity profile give rise to information concerning the probability of a region's antigenicity.
  • Efficient detection systems for infection with pathogenic microorganisms may include the use of panels of epitopes.
  • the epitopes in the panel may be constructed into one or multiple polypeptides. At least one of the epitopes will be encoded in pilC or derived from PilC.
  • the assays for the varying epitopes may be sequential or simultaneous.
  • Kits suitable for immunodiagnosis and contain ⁇ ing the appropriate labeled reagents are constructed by packaging the appropriate materials, including the polypeptides of the invention containing PilC epitopes (i.e., epitopes encoded within pilC) or antibodies directed against PilC epitopes in suitable containers.
  • the kit may also contain other reagents, for example, buffer and standard, as well as other materials required for the conduct of the assay, as well as a suitable set of instructions for conducting the assay using the kit materials.
  • oligomers are oligomers. Using the disclosed portions of the pilC DNAs as a basis, oligomers of approximately 8 nucleotides or more can be prepared, either by excision from recombinant polynucleotides or by synthetic methods which are known in the art. These oligomers can serve as probes for the detection (including isolation and/or labeling) of polynucleotides which contain pilC sequences, and/or as primers for the transcription and/or replication of targeted pilC sequences.
  • the oligomers contain a targeting polynucleotide sequence, which is comprised of nucleotides which are complementary to a target pile nucleotide sequence; the sequence is of sufficient length and complementarity with the pilC sequence to form a duplex which has sufficient stability for the purpose intended.
  • a targeting polynucleotide sequence which is comprised of nucleotides which are complementary to a target pile nucleotide sequence; the sequence is of sufficient length and complementarity with the pilC sequence to form a duplex which has sufficient stability for the purpose intended.
  • the oligomers would contain a polynucleotide region which is of sufficient length and complementarity to the targeted pilC sequence to afford sufficient duplex stability to immobilize the analyte on a solid surface, via its binding to the oligomers, under the isolation conditions.
  • the oligomers are to serve as primers for the transcription and/or replication of target pilC sequences in an analyte polynucleotide
  • the oligomers would contain a polynucleotide region of sufficient length and complementarity to a region flanking the targeted pilC sequence to allow the polymerizing agent to continue replication from the primers which are in stable duplex form with the target sequence, under the polymerizing conditions.
  • the oligomers may contain a minimum of about 4 contiguous nucleotides which are complementary to a targeted pilC sequence; usually the oligomers will contain a minimum of about 8 contiguous nucleotides which are complementary to the targeted pilC sequence, and preferably will contain a minimum of about 14 contiguous nucleotides which are complementary to the targeted pilC sequence.
  • the oligomer need not consist only of the sequence which is complementary to the targeted pilC sequence. It may contain in addition, nucleotide sequences or other moieties which are suitable for the purposes for which the oligomers are used. For example, if the oligomers are used as primers for the amplification of targeted pilC sequences via the polymerase chain reaction (PCR) , they may contain sequences which, when in duplex, form restriction enzyme sites which facilitate the cloning of the amplified sequences. Other types of moieties or sequences which are useful of which the oligomers may be comprised or coupled to, are those which are known in the art to be suitable for a variety of purposes, including the labeling of nucleotide probes.
  • PCR polymerase chain reaction
  • nucleic acid hybridization assay single-stranded analyte nucleic acid (either DNA or RNA) is hybridized to a nucleic acid probe, and resulting duplexes are detected.
  • sequences of interest are a length which allows the detection of these sequences by hybridization. While 6-8 nucleotides may be a workable length, sequences of
  • probes can be prepared using routine methods, including automated oligonucleotide synthetic methods. For use as probes, complete complementarity is desirable, although it may be unnecessary as the length of the fragment is increased.
  • the sample to be analyzed For use of such probes as agents to detect the presence of pilC sequences, the sample to be analyzed
  • nucleic acid sample (which may be biological) may be treated, if desired, to extract the nucleic acids contained therein.
  • the resulting nucleic acid from the sample may be subjected to gel electrophoresis or other size separation techniques; alternatively, the nucleic acid sample may be dot blotted without size separation.
  • the targeted region of the analyte nucleic acid In order to form hybrid duplexes with the targeting sequence of the probe, the targeted region of the analyte nucleic acid must be in single-stranded form. The latter may occur naturally; alternatively, it may be accomplished by denaturation. Denaturation can be accomplished by various techniques known in the art.
  • the analyte nucleic acid and probe are incubated under conditions which promote stable hybrid formation of the target sequence in the probe with the putative targeted sequence in the analyte, and the resulting duplexes containing probe(s) are detected.
  • Detection of the resulting duplex is usually accomplished by the use of labeled probes; alternatively, the probe may be unlabeled, but may be detectable by specific binding with a ligand which is labeled, either directly or indirectly.
  • Suitable labels, and methods for labeling probes and ligands are known in the art, and include, for example, radioactive labels which may be incorporated by known methods (e.g., nick translation or kinasing) , biotin, fluorescent groups, chemiluminescent groups (e.g., doxetanes, particularly triggered dioxetands) , enzymes, antibodies, and the like. Variations of this basic scheme are known in the art.
  • the targeted pilC sequences are expected to be present at relatively low levels, amplification may be required for their detection.
  • amplification may be required for their detection.
  • Such techniques are known in the art.
  • the Enzo Biochemical Corporation "Bio-Bridge" system uses terminal deoxynucleotide transferase to add unmodified 3' -poly-dT-tails to a DNA probe.
  • the poly dT-tailed probe is hybridized to the target nucleotide sequence, and then to a biotin-modified poly-A.
  • PCT application 84/03520 and EPA124221 describe a DNA hybridization assay in which: (1) analyte is annealed to a single-stranded DNA probe that is complementary to an enzyme-labeled oligonucleotide; and (2) the resulting tailed duplex is hybridized to an enzyme-labeled oligonucleotide.
  • EPA 204510 describes a DNA hybridization assay in which analyte DNA is contacted with a probe that has a tail, such as a poly-dT tail, an amplifier strand that has a sequence that hybridizes to the tail of the probe, such as a poly- sequence, and which is capable of binding a plurality of labeled strands.
  • a particularly desirable technique may first involve amplification of the target pilC sequences.
  • the target pilC sequences in sera may be amplified, for example, to approximately 10 sequences/ml. This may be accomplished, for example, by the polymerase chain reactions (PCR) technique described by Saiki et al. (1986), by Mullis, U.S. Patent No. 4,683,195, and by Mullis et al. U.S. Patent No. 4,683,202.
  • Amplification may be prior to, or preferably subsequent to purification of the pilC target sequence.
  • amplification may be utilized in conjunction with the assay methods described in U.S. Patent No. 4,868,105, or if even further amplification is desired, in conjunction with the hybridization system in EPO Publication No. 317,077.
  • oligonucleotide primers are prepared which match opposite ends of a desired sequence.
  • the sequence between the primers need not be known.
  • a sample of polynucleotide is extracted and denatured, preferably by heat, and hybridized with oligomers which are oligonucleotide primers, which are present in molar excess. Polymerization is catalyzed by a template- and primer- dependent polymerase in the presence of deoxynucleotide triphosphates (dNTPs) , and may also be in the presence of nucleotide analogs.
  • dNTPs deoxynucleotide triphosphates
  • the replicated DNA is again denatured, hybridized with oligonucleotide primers, returned to polymerizing conditions, and a second cycle of replication is initiated.
  • the second cycle provides the two original strands, the two long products from cycle 1, and two "short products” replicated from the long products.
  • the short products contain sequences (sense or antisense) derived from the target sequence, flanked at the 5'- and 3'-termini with primer sequences.
  • the number of short products is replicated exponentially. Thus, this process causes amplification of a specific target sequence.
  • primer may refer to more than one primer, particularly in the case where there is some ambiguity in the information regarding the terminal sequence(s) of the target region to be amplified.
  • a “primer” includes a collection of primer oligonucleotides containing sequences representing the possible variations in the sequence or includes nucleotides which allow a typical base pairing.
  • One of the primer oligomers in this collection will be homologous with the end of the target sequence.
  • the amplified sequence(s) may then be detected using a hybridization assay which utilize nucleic acid multimers which bind to single-stranded analyte nucleic acid, and which also bind to a multiplicity of single-stranded labeled oligonucleotides.
  • a suitable solution phase sandwich assay which may be used with labeled polynucleotide probes, and the methods for the preparation of probes is described in EPO 225,807, published June 16, 1987.
  • the probes can be packaged into diagnostic kits. Diagnostic kits include the probe DNA, which may be labeled; alternatively, the probe DNA may be unlabeled and the ingredients for labeling may be included in the kit in separate containers.
  • the kit may also contain other suitably packaged reagents and materials needed for the particular hybridization protocol, for example, standards, buffers, as well as instructions for conducting the test using the kit ingredients.
  • the pilC DNA sequence information in the clones described in the Examples may be used to gain further information on the remaining sequence of the pilC gene from meningococci, for other possible alleles of pilC in Neisseria, as well as pilC in other relevant genuses and species. This information will aid in the characterization of the gene, and of its role in virulence of the pathogenic forms of microorganisms, including, for example, Neisseria, Pseudomonas,
  • the DNA sequence information in the above-mentioned clones is useful for the design of probes for the isolation of additional DNA sequences which are derived from as yet undefined regions of pilC.
  • labeled probes containing a sequence of approximately 8 or more nucleotides, and preferably 20 or more nucleotides, which are derived from regions close to the ends of the DNA sequences shown in the Examples may be used to isolate overlapping DNA sequences within or adjacent to pilC from DNA libraries created from genomes of species having type 4 pilins.
  • the resulting overlapping DNAs may then be used to synthesize probes for identification of other overlapping fragments which do not necessarily overlap the DNAs whose sequences are given in the Examples.
  • sequence entire pilC genes utilizing the DNA sequences provided herein and the technique of isolation of overlapping DNAs derived from the pilC genes.
  • DNA libraries which are useful for screening with nucleic acid probes may also be constructed in other vectors known in the art, for example, lambda-gtlO (Huynh et al. (1985) ) .
  • Another suitable vector for the creation of libraries may be EMBL3, which is a replacement vector which accepts inserts ranging from 9 to 23 kb in size.
  • methods for constructing DNA libraries is discussed in Maniatis et al, MOLECULAR CLONING, 2nd edition, (1989) .
  • sequence information derived from these overlapping pilC DNAs is useful for determining areas of homology and heterogeneity within the pilC gene(s), which could indicate the presence of different strains gonococci, meningococci, or other hitherto unrecognized pathogenic forms of Neisseria. It is also useful for the design of hybridization probes to detect PilC antigens or pilC nucleic acids in biological samples.
  • the overlapping DNAs may be used to create expression vectors for polypeptides derived from pile gene(s) .
  • the pile DNA sequence information may also allow the construction of additional bacteriostatic agents for treatment of neisserial infections, in that they may block the expression of PilC and/or pilin assembly.
  • Antisense polynucleotides molecules are comprised of a complementary nucleotide sequence which allows them to hybridize specifically to designated regions of genomes or RNAs.
  • Antisense polynucleotides may include, for example, molecules that will block protein translation by binding to mRNA, or may be molecules which prevent replication of DNA by replicase. They may also include molecules which carry agents (non-covalently attached or covalently bound) which cause the mRNA or genomic DNA to be inactive by causing, for example, scissions in these molecules.
  • Antisense molecules which are to hybridize to pilC derived polynucleotides may be designed based upon the sequence information of the pilC DNA sequences provided herein, including those which would be isolated from additional DNA libraries.
  • the antibacterial agents based upon anti-sense polynucleotides for pilC may be designed to bind with high specificity, to be of increased solubility, to be stable, and to have low toxicity. Hence, they may be delivered in specialized systems, for example, liposomes, or by gene therapy. In addition, they may include analogs, attached proteins, substituted or altered bonding between bases, etc.
  • drugs may be based upon polynucleotides which "mimic" important control regions of the pilC gene, and which may be therapeutic due to their interactions with key components of the system responsible for expression of the gene.
  • DNA library, sequencing clones, constructing expression vectors, transforming cells, performing immunological assays such as radioimmunoassays and ELISA assays, for rowing cells in culture, and the like are known in the rt and laboratory manuals are available describing these techniques.
  • immunological assays such as radioimmunoassays and ELISA assays, for rowing cells in culture, and the like
  • prokaryotic and eukaryotic host cells may be used for expression of desired coding sequences when appropriate control sequences which are compatible with the designated host are used.
  • E. coli is most frequently used.
  • Expression control sequences for prokaryotes include promoters, optionally containing operator portions, and ribosome binding sites.
  • Transfer vectors compatible with prokaryotic hosts are commonly derived from, for example, pBR322, a plasmid containing operons conferring ampicillin and tetracycline resistance, and the various pUC vectors, which also contain sequences conferring antibiotic resistance mark ⁇ ers. These markers may be used to obtain successful transformants by selection.
  • prokaryotic control sequences include the Beta-lactamase (penicillinase) and lactose promoter systems (Chang et al. (1977)), the tryptophan (trp) promoter system (Goeddel et al. (1980) ' ) and the lambda-derived P ⁇ promoter and N gene ribosome binding site (Shimatake et al. (1981)) and the hybrid tac promoter (De Boer et al. (1983)) derived from sequences of the trp and lac UV5 promoters.
  • the foregoing systems are particularly compatible with E.
  • Eukaryotic hosts include yeast and mammalian cells in culture systems. Saccharo yces cerevisiae and Saccharomyces carl sber gens is are the most commonly used yeast hosts, and are convenient fungal hosts.
  • Yeast compatible vectors carry markers which permit selection of successful transformants by conferring prototrophy to auxotrophic mutants or resistance to heavy metals on wild-type strains. Yeast compatible vectors may employ the 2 micron origin of replication (Broach et al.
  • control sequences for yeast vectors are known in the art and include promoters for the synthesis of glycolytic enzymes (Hess et al. (1968) ; Holland et al. (1978)), including the promoter for 3 phosphoglycerate kinase (Hitzeman (1980)). Terminators may also be included, such as those derived from the enolase gene (Holland (1981) ) .
  • Particularly useful control systems are those which comprise the glyceraldehyde-3 phosphate dehydrogenase (GAPDH) promoter or alcohol dehydrogenase (ADH) regulatable promoter, terminators also derived from GAPDH, and if secretion is desired, leader sequence from yeast alpha factor.
  • GAPDH glyceraldehyde-3 phosphate dehydrogenase
  • ADH alcohol dehydrogenase
  • the transcriptional regulatory region and the transcriptional initiation region which are operably linked may be such that they are not naturally associated in the wild-type organism.
  • Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC) , including HeLa cells, Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK) cells, and a number of other cell lines.
  • ATCC American Type Culture Collection
  • CHO Chinese hamster ovary
  • BHK baby hamster kidney
  • Suitable promoters for mammalian cells are also known in the art and include viral promoters such as that from Simian
  • Virus 40 (SV40) (Fiers (1978)), Rous sarcoma virus (RSV) , adenovirus (ADV) , and bovine papilloma virus (BPV) .
  • Mammalian cells may also require terminator sequences and poly A addition sequences; enhancer sequences which increase expression may also be included, and sequences which cause amplification of the gene may also be desirable. These sequences are known in the art.
  • Vectors suitable for replication in mammalian cells are known in the art, and may include viral replicons, or sequences which insure integration of the appropriate sequences encoding PilC epitopes into the host genome.
  • a vector which is used to express foreign DNA, and which may be used in vaccine preparation is Vaccinia virus.
  • the heterologous DNA is inserted into the Vaccinia genome.
  • Techniques for the insertion of foreign DNA into the vaccinia virus genome are known in the art, and utilize, for example, homologous recombination.
  • the insertion of the heterologous DNA is generally into a gene which is non-essential in nature, for example, the thymidine kinase gene (tk) , which also provides a selectable marker.
  • Plasmid vectors that greatly facilitate the construction of recombinant viruses have been described (see, for example, Mackett et al. (1984), Chakrabarti et al. (1985); Moss (1987)).
  • polypeptide containing at least one immunoreactive PilC epitope then occurs in cells or individuals which are immunized with the live recombinant vaccinia virus.
  • Other systems for expression of desired polypeptides include insect cells and vectors suitable for use in these cells. These systems are known in the art, and include, for example, insect expression transfer vectors derived from the baculovirus Autographa californica nuclear polyhedrosis virus (AcNPV) , which is a helper-independent, viral expression vector. Expression vectors derived from this system usually use the strong viral polyhedrin gene promoter to drive expression of heterologous genes. Currently the most commonly used transfer vector for introducing foreign genes into AcNPV is pAc373.
  • vectors known to those of skill in the art, have also been designed for improved expression. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and which introduces a BamHI cloning site 32 basepairs downstream from the ATT; See Luckow and Summers (1989)) .
  • the insertion can be into a gene such as the polyhedrin gene, by homologous recombination; insertion can also be into a restriction enzyme site engineered into the desired baculovirus gene.
  • the inserted sequences may be those which encode all or varying segments of the polyprotein, or other orfs which encode viral polypeptides.
  • the insert could encode the following numbers of amino acid segments from the polyprotein: amino acids 1-1078; amino acids 332-662; amino acids 406-662; amino acids 156-328, and amino acids 199-328.
  • the signals for posttranslational modifications such as signal peptide cleavage, proteolytic cleavage, and phosphorylation, appear to be recognized by insect cells.
  • the signals required for secretion and nuclear accumulation also appear to be conserved between the invertebrate cells and vertebrate cells. Examples of the signal sequences from vertebrate cells which are effective in invertebrate cells are known in the art, for example, the human interleukin 2 signal (IL2 ) which is a signal for transport out of the cell, is recognized and properly removed in insect cells.
  • IL2 human interleukin 2 signal
  • Recombinant polynucleotides are inserted into host cells by transformation. Transformation may be by any known method for introducing polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus and transducing a host cell with the virus, and by direct uptake of the polynucleotide. The transformation procedure used depends upon the host to be transformed. Bacterial transformation by direct uptake generally employs treatment with calcium or rubidium chloride (Cohen (1972); Maniatis (1989)). Yeast transformation by direct uptake may be carried out using the method of Hinnen et al. (1978) .
  • Mammalian transformations by direct uptake may be conducted using the calcium phosphate precipitation method of Graham and Van der Eb (1978) , or the various known modifications thereof.
  • Other methods for the introduction of recombinant polynucleotides into cells, particularly into mammalian cells, which are known in the art include dextran-mediated transfection, calcium phosphate mediated transfection, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the polynucleotides into nuclei.
  • the recombinant polynucleotide may be in the form of a vector.
  • Vector construction employs techniques which are known in the art. Site-specific DNA cleavage is performed by treating with suitable restriction enzymes under conditions which generally are specified by the manufacturer of these commercially available enzymes.
  • cleaved fragments In general, about 1 microgram of plasmid or DNA sequence is cleaved by 1 unit of enzyme in about 20 microliters buffer solution by incubation of 1-2 hr at 37 C. After incubation with the restriction enzyme, protein is removed by phenol/chloroform extraction and the DNA recovered by precipitation with ethanol. The cleaved fragments may be separated using polyacrylamide or agarose gel electrophoresis techniques, according to the general procedures found in Methods in Enzymology (1980)
  • Sticky ended cleavage fragments may be blunt ended using E. coli DNA polymerase I (Klenow) in the presence of the appropriate deoxynucleotide triphosphates (dNTPs) present in the mixture. Treatment with SI nuclease may also be used, resulting in the hydrolysis of any single stranded DNA portions.
  • E. coli DNA polymerase I Klenow
  • dNTPs deoxynucleotide triphosphates
  • Ligations are carried out using standard buffer and temperature conditions using T4 DNA ligase and ATP; sticky end ligations require less ATP and less ligase than blunt end ligations.
  • the vector fragment is often treated with bacterial alkaline phosphatase (BAP) or calf intestinal alkaline phosphatase to remove the 5'-phosphate and thus prevent religation of the vector; alternatively, restriction enzyme digestion of unwanted fragments can be used to prevent ligation.
  • BAP bacterial alkaline phosphatase
  • calf intestinal alkaline phosphatase calf intestinal alkaline phosphatase
  • Ligation mixtures are transformed into suitable cloning hosts, such as E. coli, and successful transformants selected by, for example, antibiotic resistance, and screened for the correct construction.
  • suitable cloning hosts such as E. coli
  • successful transformants selected by, for example, antibiotic resistance, and screened for the correct construction.
  • the desired recombinant DNA sequences may be synthesized by synthetic methods. Synthetic oligonucleotides may be prepared using an automated oligonucleotide synthesizer as described by Warner
  • the synthetic strands may be labeled with 32P by treatment with polynucleotide kinase in the presence of 32P-ATP, using standard conditions for the reaction.
  • DNA sequences may be modified by known techniques, including, for example site directed mutagenesis, as described by Zoller (1982) . Briefly, the DNA to be modified is packaged into phage as a single stranded sequence, and converted to a double stranded DNA with DNA polymerase using, as a primer, a synthetic oligonucleotide complementary to the portion of the DNA to be modified, and having the desired modification included in its own sequence. The resulting double stranded DNA is transformed into a phage supporting host bacterium. Cultures of the transformed bacteria, which contain replications of each strand of the phage, are plated in agar to obtain plaques.
  • DNA libraries may be probed using the procedure of Grunstein and Hogness (1975) . Briefly, in this procedure, the DNA to be probed is immobilized on nitro ⁇ cellulose filters, denatured, and prehybridized with a buffer containing 0-50% formamide, 0.75 M NaCl, 75 mM Na citrate, 0.02% (wt/v) each of bovine serum albumin, poly- vinyl pyrollidone, and Ficoll, 50 mM Na Phosphate (pH 6.5), 0.1% SDS, and 100 micrograms/ml carrier denatured DNA. The percentage of formamide in the buffer, as well as the time and temperature conditions of the prehybridization and subsequent hybridization steps depends on the stringency required.
  • Oligomeric probes which require lower stringency conditions are generally used with low percentages of formamide, lower temperatures, and longer hybridization times.
  • Probes containing more than 30 or 40 nucleotides such as those derived from cDNA or genomic sequences generally employ higher temperatures, e.g., about 40-42°C, and a high percentage, e.g., 50%, formamide.
  • 5'- 32P-labeled oligonucleotide probe is added to the buffer, and the filters are incubated in this mixture under hybridization conditions. After washing, the treated filters are subjected to autoradiography to show the location of the hybridized probe; DNA in corresponding locations on the original agar plates is used as the source of the desired DNA.
  • ligation mixtures are transformed into E. coli strain HB101 or other suitable host, and successful transformants selected by antibiotic resistance or other markers.
  • Plasmids from the transformants are then prepared according to the method of Clewell et al. (1969), usually following chloramphenicol amplification (Clewell (1972)).
  • the DNA is isolated and analyzed, usually by restriction enzyme analysis and/or sequencing. Sequencing may be by the dideoxy method of Sanger et al. (1977) as further described by Messing et al. (1981), or by the method of Maxam et al. (1980) . Problems with band compression, which are sometimes observed in GC rich regions, were overcome by use of T-deazoguanosine according to Barr et al. (1986).
  • An enzyme-linked immunosorbent assay can be used to measure either antigen or antibody concentrations. This method depends upon conjugation of an enzyme to either an antigen or an antibody, and uses the bound enzyme activity as a quantitative label.
  • the known antigen is fixed to a solid phase (e.g., a microplate or plastic cup), incubated with test serum dilutions, washed, incubated with anti-immunoglobulin labeled with an enzyme, and washed again.
  • Enzymes suitable for labeling are known in the art, and include, for example, horseradish peroxidase.
  • Enzyme activity bound to the solid phase is measured by adding the specific substrate, and determining product formation or substrate utilization colorimetrically. The enzyme activity bound is a direct function of the amount of antibody bound.
  • a known specific antibody is fixed to the solid phase, the test material containing antigen is added, after an incubation the solid phase is washed, and a second enzyme-labeled antibody is added.
  • An outer membrane preparation from N. gonorrhoeae strain MSll (P + ) contains small amounts of a 110 kd protein, PilC. This protein was enriched during alternate cycles of crystallization and solubilization of pili, unlike other outer membrane proteins that decreased in abundance by this procedure.
  • Pili were prepared essentially as described by Brinton et al. (1978). Gonococci (P + Tr) from 80 GGB plates, grown for 18 h, were harvested in 0.05 M Tris- HC1 pH 8.0 and 0.15 M NaCl, washed twice and resuspended in 40 ml 0.15 M ethanolamine pH 10.5. Pili were sheared off in a Sorvall Omnimixer, setting 3 for 30 s. The cell debris was pelleted at 13,000 g for 30 min at 4°C and the supernatant was dialyzed against 0.05 M Tris-HCl pH 8.0 and 0.15 M NaCl.
  • the 110 kd protein present in purified MSll ms pili preparations was eluted from SDS polyacrylamide gels and rabbit antibodies were generated against the' gel purified protein.
  • the antiserum cross reacted extensively with the pilin protein in immunoblots and was therefore absorbed with extracts of Pseudomonas putida expressing the pilin subunit of N. gonorrhoeae on plasmid pGC02.
  • the achieved 110 kd-antiserum was extensively absorbed with Pseudomonas putida 2440 (Bagdasarien et al. (1983), carrying a recombinant plasmid, pGC02, constructed as follows.
  • the pilE gene is then under control of the tac promoter and induction with 1 mM IPTO resulted in high levels of pilin produced in P.
  • the pili antiserum used in immunoblots was generated in a rabbit against highly purified pili preparations of N. gonorrhoeae MSll .
  • the absorbed antiserum was used in immunoblots with whole cell extracts of a number of N. gonorrhoeae strains as well as commensal strains of Neisseria ( Figure 2A) . All strains of N. gonorrhoeae, except strain 605103, contained one or two high molecular weight protein species reacting with the antiserum. Strain 605103, unlike the other strains tested, was nonpiliated and no piliated variants could be obtained suggesting that it is a P ' n variant (Swanson et al., 1985). This was confirmed by Southern blot hybridization using an oligonucleotide probe corresponding to the 5' end of the pilE gene.
  • Southern blot hybridization was accomplished as follows. Digested genomic DNA was separated on 0.7% agarose gels and transferred to nitrocellulose filters (Southern, 1975) . After transfer and baking the filters were prehybridized in a mixture of 5 x SSC, 0.1% SDS, 5 mM EDTA, 5 x Denhardt's solution and 100 ⁇ g/ml of sonicated calf thymus DNA at 65°C for 2-6 h. P-labeled probe (multiprime DNA labelling system, Amersham International) was added and hybridization was performed for 12-15 h at the same temperature.
  • P-labeled probe multiprime DNA labelling system, Amersham International
  • the filters were washed in 2 x SSC with 0.1% SDS and in 0.2 x SSC with 0.1% SDS for 2 x 15 min each, dried and exposed to Kodak XRP film at -80°C.
  • a 21-base-long oligonucleotide complementary to the signal peptide coding region of pilE (5'- GCCTTTTTGAAGGGTATTCAT-3') was 32 P-labeled with T4 polynucleotide kinase and used to probe Clal-digested genomic DNA.
  • the blot was prehybridized at 37°C in a mixture containing 2 x Denhardt's, 0.1% SDS, 2.5 mM EDTA, 5 x SSC and 100 ⁇ g/ml sonicated calf thymus DNA, hybridized at 37°C and washed in 2 x SSC for 5 min.
  • Sll j ⁇ " * " ) gave a 4 kb hybridization fragment
  • MSll mjc (P " n) and 605103 gave no hybridization signal.
  • the 800 bp insert was purified, labeled with 32P, and used as a probe to screen a plasmid library from N. gonorrhoeae MSll .
  • plasmids pABJ04-09 which all belong to locus 1, were isolated from a plasmid library using the 800 bp insert from ⁇ gtll as a probe.
  • the ⁇ gtll insert (from locus 2) has an additional Sail site not found in the plasmid clones.
  • the position of the pilCl gene and direction of its transcription (indicated.by an arrow) were determined in JE7. coli minicells.
  • the E. coli minicell strain AAIO was transformed with plasmid DNA (pABJ04-09) and chromosome deficient minicells from these strains were purified over sucrose gradients (Thompson and Achtman, 1978) .
  • the plasmid-encoded proteins were labeled in the presence of 80 ⁇ Ci [ S3methionine in minimal salts medium and 1% methionine assay medium (Difco) .
  • Plasmid pABJ04 expressed minute amounts of three high molecular weight proteins, 113, ill and 108 kd in size, as well as a number of lower molecular weight protein species not produced from the vector control.
  • the three high molecular weight bands were missing in pABJ05 and pABJ06 but three novel lower molecular weight protein species had appeared, suggesting that pABJ05 and pABJ06 are deleted for the .3' end of a gene, denoted pilCl , and that this gene is responsible for all three high molecular weight species. This suggested that the distal end of the gene must be located between the JMIuI, and Mull 2 sites ( Figure 1) .
  • the observation that plasmid pABJ07 did not express any high molecular proteins tentatively located the 5' end of the gene to a region
  • the size for a gene encoding a 110 kd protein is ⁇ 3 kb which is in agreement with these mapping data.
  • the 800 bp insert in ⁇ gtll contains a single
  • the DNA sequence of the 3' -end of the pilC2 fragment is shown in Figure 7.
  • the sequence showing the putative amino acids encoded therein are shown in Figure 8.
  • a comparison of the analogous portions of pilC2 (top) and pilCl (bottom) DNA sequences, and the putative amino acids encoded therein are shown in Figure 9.
  • the 800 bp fragment from pilC2 was also used to probe digested genomic DNA from N. gonorrhoeae strains UMOl, 765 and 605103.
  • the latter isolate does not express detectable levels of the 110 kd protein.
  • Strain UMOl unlike MSll, contained only one Clal fragment of 15 kb that hybridized to the probe (data not shown) . Hence, this strain may contain only one copy of pilC.
  • Strain 605103 and 765 each seem to contain two copies of pilC since two Clal and two Smal fragments hybridized to the 800 bp probe.
  • the pilCl gene on pABJ04 is translationally out of frame
  • the amino terminal sequence of gel purified 110 kd protein from strain MSll (P + ) was determined by sequential Edman degradation.
  • the 3.3 kb fl ⁇ . ⁇ dIII 4 - Mlul 1 fragment encompassing the entire pilCl gene was sequenced on both strands using the dideoxy sequencing method adapted for single stranded DNA.
  • Figure 2 shows the nucleotide sequence and the deduced amino acid sequence of the 5'-end of pilC.
  • the amino-terminal sequence of gel purified PilC from MSll mg (P + ) is shown in a box below frame 2, a 997 amino acid long open reading frame that would code for a protein about 110 kd in size.
  • Frame 1 contains 41 amino acids and is preceded by a putative Shine-Dalgarno sequence (underlined) .
  • Two horizontal lines mark a stretch of 12 G residues. An addition of one G in this region would align the ATG (boxed) in frame 1 with frame 2.
  • the position of two 24 bp oligonucleotide primers (opposite stands) used for PCR amplification, are indicated above the sequence by hatched bars.
  • Figure 3 shows the nucleotide sequence of the sense strand of the pilCl gene.
  • Figure 4 shows the shows the nucleotide sequence of the sense strand of the pilCl gene and the amino acids encoded therein.
  • Plasmid pABJ04 was mutagenized in E. coli by a transposon mini-Tn3 derivative, mTnCm.
  • the shuttle mutagenesis system developed by Seifert et al., (1986) using a miniTn3 carrying the chloramphenicol resistance gene was kindly provided by Dr. M. So.
  • Mutagenesis of pABJ04 with mTnCm and transformation of N. gonorrhoeae were performed as previously described (Seifert et al., 1990) .
  • MiniTnCm insertions at 30 different positions in pABJ04 were identified, two of which mapped within the PilC gene. Piliated N.
  • transformants were selected for on plates containing 10 ⁇ g/ml chloramphenicol for the single mutants and 30 ⁇ g/ml chloramphenicol for the double mutants.
  • Genomic DNA was prepared from seven of the chloramphenicol resistant transformants (five from pABJ04: :mTnCm-12 and two from pABJ04: :mTnCm-14) , cleaved with Clal and PvuII and used in Southern blot experiments using the EcoRV 1 - EcoRV 2 fragment of pABJ04 as a probe. The 8 kb Clal fragment was unaffected in the mutants whereas the 18 kb Clal fragment had been replaced by a 20 kb fragment.
  • PvuII cleaves within the 1.6 kb mTnCm element.
  • the probe detected an 8 kb PvuII fragment in both parent and mutant DNA.
  • a novel PvuII fragment appeared that was 6.2 kb in size in five transformants obtained with pABJ04: :mTnCm-12 and 4.8 kb in size in two transformants with pABJ04: :mTnCm-14.
  • a 250 bp EcoRI-Hindlll fragment of the CAT GenBlock (Pharmacia, Sweden) , containing the PvuII site, was used as a probe.
  • a P + , pilCl : :mTnCm-12 mutant was retransformed with DNA prepared from a P " , pilC2: :mTnCm-12 mutant and colonies growing at 30 ⁇ g/ml of chloramphenicol were selected to obtain double mutants in pilC. All resistant transformants were P " , and when analyzed by Southern blot hybridization all contained mTnCm in both pilCl and pilC2.
  • P + revertants occurred spontaneously at a low frequency in the pilC2 : :mTnCm-12 mutants. These revertants expressed pili as determined by electron microscopy and also expressed PilC. It is likely that PilC expression is due to in-frame switching in pilCl .
  • Figure 5 shows the nucleotide sequence of the sense strand of the pilCl gene, and the effect of frame shift on the putative gene products encoded therein.
  • the pilC genes of N. onorrhoeae vary in the length of the G tract
  • PCR Polymerase chain reaction
  • Tag polymerase was used to analyze the 5' region of pilC using two 24 base long synthetic oligonucleotides based on the sequence of pilCl ( Figure 2) . These oligonucleotides would generate an amplified fragment of
  • DNA 1.0 ⁇ M of each oligonucleotide, 200 ⁇ M of each nucleotide, 0.001% gelatin, 1.5 mM MgCl 2 , 10 mM Tris (pH 8.3), 50 mM KCl, 0.25 ⁇ l 1 mCi/ml [ 32 P]dATP and 2 U of
  • Taq Polymerase Perkin Elmer Cetus
  • the samples were passed through 25 cycles: 2 min at 50°C, 1 min at 94°C and 3 min at 72°C in a Thermal Cycler (Perkin Elmer
  • M13mpl8, and twenty phage clones were sequenced using a universal primer. Four different sequences were obtained
  • Figure 6 shows the nucleotide sequence of PCR amplified fragments demonstrating a variation in the length of the G tract and sequence differences in the 5'- region of the pilC genes.
  • the two oligonucleotide primers used for the PCR are shown in Figure 2. Amplified DNA was cloned into M13mp8 and sequenced.
  • Variant patterns la and lb were identical to each other and to the cloned sequence on pABJ04 except for the presence of 11 instead of 12 G residues in the G tract of lb.
  • the G tract of sequence 2a was 13 residues long indicating that the sequence is in frame.
  • this sequence differed from pilCl by four basepair substitutions outside the G tract, including an AAA lysine codon four triplets downstream of the putative signal peptide processing site which is in agreement with the lysine residue found in the fourth position of the gel purified 110 kd PilC protein.
  • Sequences la and lb contained CAA, the codon for Gin, at the same position.
  • Sequence 2b was identical to 2a except for the presence of 12 G residues in the G tract.
  • Strain 765 contains two pilC loci, both of which seem to be translationally ON based on the presence of two high molecular weight proteins reacting with the absorbed PilC antiserum. A number of amplified fragments were seen after the PCR reaction ranging in size from 149 to 153 bases. Three variant sequences were found among nine clones ( Figure 6) . The G tract was 13 residues long in variant 3a (in frame) and 14 (out of frame) in variant 3b whereas sequence variant 4 contained 11 G residues in the G tract. Variant sequence 4 contained four additional nucleotides (-CAGG-) distal to the G tract relative to variant sequences 1, 2 and 3, indicating that the amplified product with 11 Gs from this variant sequence is 152 long and out of frame. Two PCR amplified products 152 and 153 in length were obtained from strain 765 suggesting that in frame variants of sequence 4 might be present in the DNA prepared from this strain.
  • Strain 605103 carries two pilC copies, both of which seem to be translationally OFF.
  • the amplified fragments were 148 and 149 bases in size. Out of eight
  • N. meningitidis contains two pilC loci Southern blot hybridizations using MSll pilCl ' specific probes identified multiple fragments when meningococcal genomic DNA is digested with a variety of restriction endonucleases. PCR amplification using two 24-base oligonucleotides from the 5' end of MSll pilCl as primers yields multiple fragments ranging in size from 148 to 151 bases. DNA sequencing of fragments cloned into phage M13 identifies two classes of sequences, as in N. gonorrhoeae, which differ outside the G-tract. Variation occurred within each class with respect to the number of
  • N. meningitidis must carry two pilC loci, as does N. gonorrhoeae, which should also be under the control of translational frame shifting.
  • Both pilC loci are cloned from N. meningi tidis by generating an EMBL3 library and screening this library with pilCl " and pilC2 ⁇ specific DNA from N. gonorrhoeae strain MSll.
  • Genomic DNA from N. meningitidis is partially digested with Sau3A and fragments ranging from 9 to 20 kB are ligated into the lambda EMBL3 vector. Because of the packaging constraints of the phage, only those lambdas which contain DNA fragments of this size will be packaged (i.e., are viable).
  • the library thus constructed can be screened with genomic oligonucleotide or cloned gene probes following selection in a lysogenic E. coli strain. (Frischart, A.M. et al (1983), J. Mol. Biol. 170:827).
  • full length clones are identified by screening for clones hybridizing to both the 5' and 3' ends of pilC. If full length clones cannot be obtained from the EMBL3 library, pilC specific probes may be used to screen a plasmid library from the same strains.
  • Translational fusion proteins with ⁇ - galactosidase may also be screened for in a ⁇ gtll library, using /3-galactosidase and PilC " specific antisera in Western immunoblots.
  • jS-galactosidase-PilCl and 3-galactosidase-PilC2 fusion proteins are purified from the cytoplasm of recombinant E. coli and used to raise specific antisera.
  • PilC PilC The immunobiological properties of PilC PilC is located in the outer membrane of Neisseria. The immune response during natural infection can be assessed by screening convalescent sera for anti- PilC antibody. The presence of only two pilC loci suggests that PilC is only moderately variable, however.
  • PilC This together with its essential role in pilus biogenesis makes PilC attractive as a potential vaccine candidate.
  • a secreted fusion protein is obtained that may associate with the outer membrane.
  • the fusion proteins may accumulate in the cytoplasm as inclusion bodies.
  • the construction schemes for such fusion proteins uses techniques known in the art. TnpiioA insertions on plasmid pABJ04 in E. coli are generated, and a PhoA + phenotype is screened for as blue colonies on media containing the chromogenic substrate XP.
  • the fusion product should be able to cross the cytoplasmic membrane where it can be analyzed by Western immunoblots using an alkaline phosphatase specific antiserum and our PilC antiserum raised against gel-purified PilC2 from MSll(P + ) .
  • LacZz -.pilC fusions are generated by cloning different segments of pilC into a lacZ ⁇ containing vector used to generate translational fusions. Similar constructs are performed on each of the two pilC genes from N. meningitidis. Antisera are generated against fusion proteins after their purification using conventional protocols. These antisera are extensively adsorbed with extracts of E. coli expressing alkaline phosphatase and S-galactosidase, and used in Western immunoblots and ELISA assays against a panel of Neisseria gonorrhoeae and
  • pilCl and pilC2 genes are highly homologous in their 5' ends whereas the homology is considerably less pronounced in the central and 3' region.
  • pilC2 gene from N. gonorrhoeae MS11(P + ) is cloned and sequenced. Algorithms are used to search for potential T-cell epitopes (amphipathic helical conformation) and jS-cell epitopes. Polypeptides containing the predicted epitopes are tested to determine if they can prime mice for an enhanced immune response to PilCl and PilC2.
  • PilC antisera are used in immunoelectromicroscopy with piliated Neisseria cells as well as with purified pili to see if PilC is physically connected with the pilus fiber.
  • Neisseria is grown in the presence of different dilutions of PilC " specific antibodies. Bactericidal effect exerted by the antiserum, effects on piliation, and effects on bacterial attachment to corneal primary culture cells are monitored. Binding assays to epithelial cells are described in Tjia, K.F. et al. (1988), Graefe's Arch. Clin. Exp. Opthalmol. 226:341- 345.
  • the pilCl and pilC2 loci are part of a larger duplication that extends both 5'- and 3'- of pilC.
  • strains may contain multiple gene clusters for the same class of pili.
  • the only difference between two duplicated gene clusters pap and prs
  • mTnc ⁇ mutagenesis in the region upstream and downstream of pilCl is performed to generate allelic replacements in the pilCl and pilC2 regions on the chromosome. Since the two regions are highly homologous we expect to obtain for each insertion allelic replacements in either region.
  • Double mutants are generated as before by isolating DNA from mutants carrying insertions in the pilC2 region transforming P + variants carrying the same insertion in the pilCl region and select for transformants resistant to 30 ⁇ g/ml of chloramphenicol. These double mutants are examined for piliation, pilins expression, and binding to corneal primary culture cells.
  • Example 9 Phase variation in gonococcal pili expression can be caused by frameshift mutations in pilC If PilC is required for pilus formation, we would expect some P " progeny arising from a P + clone to accumulate unassembled pilin in the absence of PilC. Nonpiliated (P ⁇ ) colonies were derived from MSll m]c (P + ) , restreaked, and tested for the presence of PilC and pilin in immunoblots with the PilC and pili antisera. Five out of eight P " clones did not produce detectable levels of PilC, but expressed the pilin subunit. The remaining three P " clones expressed PilC but not pilin.
  • the molecular mass of the pilin subunit was the same in the P " , PilC " variants as in MSll mk (P + , PilC + ) .
  • the former in addition produced a protein reacting with the pili antiserum that was 16 kd in size. Since MSll ⁇ only contains one expression site for pilin we believe that this protein species represents a proteolytic degradation product of the pilin and may be identical to the S-pilin previously described (Haas et al., 1987).
  • Several independent P " clones were isolated from one P " , PilC " clone. They all remained PilC " and retained expression of pilin.
  • Piliated (P + ) revertants were also obtained from the same P “ , PilC " clone. These P + revertants occurred at about a tenfold lower frequency (10 " ) than P " derivatives from a P + clone. All P + revertants from a P “ , PilC " clone had regained expression of PilC. All but one expressed a pilin with the same molecular weight as the nonpiliated parent. However, the low molecular weight pilin degradation product was much less abundant in the P + , PilC " revertants. It was possible to obtain P + revertants from other P “ , PilC " clones as well, all of which expressed PilC.
  • the pilE gene from one set of PilC switches was PCR amplified and sequenced directly.
  • the P " , PilC " , pilin + variant 8 carried eight amino acid changes in the pilin relative to the parental clone MSll ⁇
  • the pilin sequence of the P + , PilC " backswitcher 8:1 was identical to variant 8.
  • the backswitching from P " to P + colony morphology was not associated with any alteration in the pilus subunit protein implying that the change in colonial morphology was due to the switch in PilC expression.
  • phase variation of gonococcal pili may not only be caused by recombination events occurring in the pilJS locus (Bergstrom et al, .1986; Swanson et al., 1986) but also by frameshift mutations in pilC.
  • Example 10 Immunogenicity of PilC
  • residues 300 to 700 of the putative PilCl protein encoded within pilCl were analyzed for antigen index, hydrophilicity, and hydrophobicity using standard computer-modelling methods.
  • the immunogenicity of a recombinant polypeptide expressed from the DNA encoding amino acids 300 to 700 was examined.
  • the region of DNA encoding amino acid residues 300 to 700 was amplified by polymerase chain reaction (PCR) using the following oligonucleotide primers.
  • primers incorporate an Ndel and a BamHI restriction endonuclease site (indicated by the underlined nucleotides) , respectively.
  • a termination codon is indicated by the underlined nucleotides.
  • the expression products after induction were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (PAGE) using an 8% acrylamide gel and the standard 25 mM Tris base / 250 mM glycine / pH 8.3 / 0.1% sodium dodecyl sulfate (SDS) electrophoresis buffer. After electrophoresis, the gel was fixed and then stained with Coomassie Blue according to standard protocols, and the production of PilC(300-700) was confirmed by the detection of the presence in the gels of an abundant, appropriately-sized peptide of approximately 46kD. In order to detect the immunogenicity of the
  • PilC(300-700) product the region of the SDS-PAGE gel containing the PilC(300-700) polypeptide was excised from parallel unstained lanes, homogenized, and the protein eluted into a buffer of 0.1% Triton X-100 in water by passive diffusion. Rabbits were given a priming intradermal injection of homogenized gel slices (containing approximately 500 ⁇ g PilC(300-700) protein), followed 3 weeks later by a subcutaneous boost (of approximately 500 ⁇ g of eluted protein) . An initial test serum was then collected after an additional 14 days. All of the test animals yielded a specific high titer antibody response. The antibodies induced by PilC(300- 700) were immunologically reactive not only with that polypeptide (i.e., PilCl(300-700) ) , but also with native PilCl and native PilC2.
  • PilC contains antigenic epitopes that can elicit a strong immunogenic response. At least some of the immunogenic epitopes are shared (cross-reactive) between PilCl and PilC2, despite differences in primary amino acid sequence.
  • the technique of subcloning discrete portions of the PilC protein under control of an inducible promoter allows mapping of antigenic epitopes. Sufficient quantities of specific oligopeptides of known antigenicity can be produced for use in screening the in vivo immune response after exposure to the intact pathogen.
  • the invention in the various manifestations disclosed herein, has many industrial uses, some of which are the following.
  • the pilC DNAs may be used for the design of probes for the detection of pilC nucleic acids in samples.
  • the probes derived from the DNAs may be used to detect pilC nucleic acids in, for example, chemical synthetic reactions.
  • the polynucleotide probes are also useful in detecting viral nucleic acids in humans, and thus, may serve as a basis for diagnosis of pathogenic microorganisms containing type 4 pilin, for example, gonococcal and/or meningococcal infections in humans.
  • the DNAs provided herein provide information and a means for synthesizing polypeptides containing epitopes of PilC. These polypeptides are useful in detecting antibodies to PilC antigens. A series of immunoassays the relevant neisserial infection, based on recombinant polypeptides containing pilC epitopes are described herein, and will find commercial use in diagnosing diseases caused by these microorganisms. In addition, the polypeptides derived from the pilC DNAs disclosed herein will have utility as vaccines for treatment of infections caused by meningococci and gonococci.
  • the polypeptides derived from the pilC DNAs are also useful for raising anti-PilC antibodies.
  • they may be used in vaccines against the relevant microorganisms.
  • the antibodies produced as a result of immunization with the polypeptides containing an immunoreactive PilC epitope are also useful as passive vaccines, or in the detection of the presence of PilC antigens in samples.
  • they may be used to assay the production of polypeptides derived from PilC in chemical systems.
  • the anti-PilC antibodies may also be used to monitor the efficacy of anti-neisserial agents in screening programs where these agents are tested in tissue culture systems.
  • anti-PilC antibodies Another important use for anti-PilC antibodies is in affinity chromatography for the purification of PilC derived polypeptides.
  • the purified PilC polypeptide preparations may be used in vaccines.
  • the anti-PilC antibodies and polypeptides containing regions encoded in pilC, whether natural or recombinant, may be packaged into kits.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Nous avons isolé et caractérisé une nouvelle protéine des formes pathogènes de Neisseria. Nous avons également isolé et caractérisé des gènes qui encodent PilC, c'est-à-dire les loci pilC. Des portions des séquences d'ADN des gènes pilC sont utiles comme sondes pour diagnostiquer la présence des microorganismes pertinents renfermant de la piline type 4, par exemple Neisseria dans des échantillons. Ces ADN fabriquent également des séquences polypeptidiques disponibles d'épitopes immunoréactifs encodés à l'intérieur des loci, permettant ainsi la production de polypeptides qui sont utiles comme étalons ou réactifs dans des tests diagnostiques et/ou comme constituants de vaccins. Des anticorps, à la fois monoclonaux et polyclonaux purifiés, dirigés contre des épitopes PilC sont également utiles pour des tests diagnostiques et comme agents thérapeutiques pour l'immunisation passive. En outre, grâce à l'utilisation de sondes dérivées des séquences d'ADN, il est possible d'isoler et de séquencer d'autres portions des loci pilC à partir d'espèces et de souches données.
PCT/US1992/000863 1991-01-31 1992-01-31 Polypeptides et polynucleotides utiles pour le diagnostic et le traitement de neisseria pathogene WO1992013871A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64878191A 1991-01-31 1991-01-31
US648,781 1991-01-31

Publications (1)

Publication Number Publication Date
WO1992013871A1 true WO1992013871A1 (fr) 1992-08-20

Family

ID=24602214

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/000863 WO1992013871A1 (fr) 1991-01-31 1992-01-31 Polypeptides et polynucleotides utiles pour le diagnostic et le traitement de neisseria pathogene

Country Status (2)

Country Link
AU (1) AU1411492A (fr)
WO (1) WO1992013871A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008013A1 (fr) * 1992-10-07 1994-04-14 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Variantes de piline et leurs utilisations
WO1995006749A1 (fr) * 1993-09-03 1995-03-09 Abbott Laboratories OLIGONUCLEOTIDES ET PROCEDES DE DETECTION DE $i(NEISSERIA GONORRHOEAE)
DE4336530C1 (de) * 1993-10-26 1995-04-13 Max Planck Gesellschaft Rekombinante PilC-Proteine, Verfahren zu ihrer Herstellung und ihre Verwendung
WO1996009395A2 (fr) * 1994-09-21 1996-03-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Medicament destine a la prophylaxie et au traitement de maladies auto-immunes et virales, agents de diagnostic pour le depistage desdites maladies
WO1997011181A1 (fr) * 1995-09-18 1997-03-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Molecules d'acide nucleique codant des proteines jouant un role de mediation dans l'adhesion de cellules de bacteries neisseria a des cellules humaines
WO1999055875A2 (fr) * 1998-04-29 1999-11-04 American Cyanamid Company VACCINS CONTENANT DE LA PILINE DE RECOMBINAISON UTILISES CONTRE LES MALADIES PROVOQUEES PAR NEISSERIA GONORRHOEAE OU $i(NEISSERIA MENINGITIDIS)
WO1999057280A2 (fr) * 1998-05-01 1999-11-11 Chiron Corporation Compositions et antigenes a base de meningocoque
US6756493B1 (en) * 1998-09-01 2004-06-29 Antex Biologics, Inc. Nucleic acid sequence and uses thereof
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
US8198430B2 (en) 2002-05-31 2012-06-12 The Secretary Of State For Defence Immunogenic sequences
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
US8609108B2 (en) 2009-04-14 2013-12-17 The Secretary Of State For Defence Gamma-glutamyl transpeptidase attenuated Francisella

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443431A (en) * 1981-05-27 1984-04-17 The United States Of America As Represented By The Department Of Health And Human Services Neisseria gonorrhoeae vaccine
US4584195A (en) * 1984-06-21 1986-04-22 The Board Of Trustees Of The Leland Stanford Junior University Broad spectrum vaccine against gonorrhea

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443431A (en) * 1981-05-27 1984-04-17 The United States Of America As Represented By The Department Of Health And Human Services Neisseria gonorrhoeae vaccine
US4584195A (en) * 1984-06-21 1986-04-22 The Board Of Trustees Of The Leland Stanford Junior University Broad spectrum vaccine against gonorrhea

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF BACTERIOLOGY, Volume 130, Number 1, issued April 1977, SWANEY et al., "Genetic Complementation Analysis of Escherichia Coli Type 1 Somatic Pilus Mutants", pages 506-511. *
JOURNAL OF BACTERIOLOGY, Volume 170, Number 4, issued April 1988, PERRY et al., "Neisseria Meningitidis C114 Contains silent, Truncated Pilin Genes that are Homologous to Neisseria Gonorrhoeae Pil Sequences", pages 1691-1697. *
JOURNAL OF BACTERIOLOGY, Volume 172, Number 6, issued June 1990, NUNN et al., "Products of three Accessory Genes, Pilb, Pilc, Pild, are Required for Biogenesis of Pseudomomas Aeruginosa Pili", pages 2911-2919. *
JOURNAL OF GENERAL MICROBIOLOGY, Volume 132, issued 1986, TINSLEY et al., "Variation in the Expression of Pili and Outer Membrane Protein by Neisseria Meningitidis during the course of Meningococcal Infection", pages 2483-2490. *
NEW ENGLAND BIOLABS CATALOG, issued 1986, (NEW ENGLAND BIOLABS, BEVERLY MASSACHUSETTS, 1986), page 60, see especially linker # 1096 compared to the instant application figure 3 at Bases 3196-3202. *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (USA), Volume 84, issued December 1987, HAAS et al., "Release of Soluble Pilin Antigen Coupled with Gene Conversion in Neisseria Gonorrhoeae", pages 9079-9083. *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (USA, Volume 81, issued October 1984, MEYER et al., "Pilus Genes of Neisseria Gonorrheae : Chromosomal Organization and DNA Sequence", pages 6110-6114. *
SIGMA CHEMICAL COMPANY CATALOG, issued 1990, (SIGMA CHEMICAL COMPANY, ST. LOUIS, MISSOURI, 1990), pages 859-860, see especially Poly(C)-(dG)12-18 on page 859 and Polydeoxyguanylic acid on page 860 compared to the instant application in figure 3 at bases 461-472. *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 254, Number 9, issued 10 May 1979, KELLEY et al., "A Rapid Procedure for isolation of large Quantities of Escherichia Coli DNA Polymerase I Utilizing a Lambda-pol a Transducing Phage", pages 3206-3210. *

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453355A (en) * 1990-01-26 1995-09-26 Abbott Laboratories Oligonucleotides and methods for the detection of Neisseria gonorrhoeae
WO1994008013A1 (fr) * 1992-10-07 1994-04-14 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Variantes de piline et leurs utilisations
WO1995006749A1 (fr) * 1993-09-03 1995-03-09 Abbott Laboratories OLIGONUCLEOTIDES ET PROCEDES DE DETECTION DE $i(NEISSERIA GONORRHOEAE)
DE4336530C1 (de) * 1993-10-26 1995-04-13 Max Planck Gesellschaft Rekombinante PilC-Proteine, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0725792B1 (fr) * 1993-10-26 2004-12-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PROCEDE DE PREPARATION DES PROTEINES PilC RECOMBINANTES
EP1520860A3 (fr) * 1993-10-26 2005-12-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protéine PilC recombinante, méthode pour sa production et son utilisation
US6268171B1 (en) * 1993-10-26 2001-07-31 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Recombinant PilC proteins, methods for producing them and their use
WO1996009395A2 (fr) * 1994-09-21 1996-03-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Medicament destine a la prophylaxie et au traitement de maladies auto-immunes et virales, agents de diagnostic pour le depistage desdites maladies
WO1996009395A3 (fr) * 1994-09-21 1996-07-18 Max Planck Gesellschaft Medicament destine a la prophylaxie et au traitement de maladies auto-immunes et virales, agents de diagnostic pour le depistage desdites maladies
WO1997011181A1 (fr) * 1995-09-18 1997-03-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Molecules d'acide nucleique codant des proteines jouant un role de mediation dans l'adhesion de cellules de bacteries neisseria a des cellules humaines
US8114971B2 (en) 1995-09-18 2012-02-14 Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acid molecules encoding proteins which impart the adhesion of Neisseria cells to human cells
WO1999055875A3 (fr) * 1998-04-29 2000-04-13 American Cyanamid Co VACCINS CONTENANT DE LA PILINE DE RECOMBINAISON UTILISES CONTRE LES MALADIES PROVOQUEES PAR NEISSERIA GONORRHOEAE OU $i(NEISSERIA MENINGITIDIS)
WO1999055875A2 (fr) * 1998-04-29 1999-11-04 American Cyanamid Company VACCINS CONTENANT DE LA PILINE DE RECOMBINAISON UTILISES CONTRE LES MALADIES PROVOQUEES PAR NEISSERIA GONORRHOEAE OU $i(NEISSERIA MENINGITIDIS)
EP2261356A3 (fr) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261339A3 (fr) * 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP1944371A3 (fr) * 1998-05-01 2008-10-08 Novartis Vaccines and Diagnostics, Inc. Antigènes de neisseria meningitidis et compositions
US7576176B1 (en) 1998-05-01 2009-08-18 Novartis Vaccines And Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US9266929B2 (en) 1998-05-01 2016-02-23 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
US7988979B2 (en) 1998-05-01 2011-08-02 J. Craig Venter Institute, Inc. Neisseria meningitidis antigens and compositions
EP2261346A3 (fr) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261342A3 (fr) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261344A3 (fr) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261338A3 (fr) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261340A3 (fr) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
WO1999057280A3 (fr) * 1998-05-01 2000-08-24 Chiron Corp Compositions et antigenes a base de meningocoque
EP2261350A3 (fr) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261352A3 (fr) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261341A3 (fr) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261345A3 (fr) * 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261355A3 (fr) * 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261347A3 (fr) * 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261349A3 (fr) * 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
US9249198B2 (en) 1998-05-01 2016-02-02 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
EP2261357A3 (fr) * 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261351A3 (fr) * 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261354A3 (fr) * 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261353A3 (fr) * 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261343A3 (fr) * 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
EP2261348A3 (fr) * 1998-05-01 2012-01-25 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
WO1999057280A2 (fr) * 1998-05-01 1999-11-11 Chiron Corporation Compositions et antigenes a base de meningocoque
US9249196B2 (en) 1998-05-01 2016-02-02 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
US9139621B2 (en) 1998-05-01 2015-09-22 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
US8524251B2 (en) 1998-05-01 2013-09-03 J. Craig Venter Institute, Inc. Neisseria meningitidis antigens and compositions
US6756493B1 (en) * 1998-09-01 2004-06-29 Antex Biologics, Inc. Nucleic acid sequence and uses thereof
US8198430B2 (en) 2002-05-31 2012-06-12 The Secretary Of State For Defence Immunogenic sequences
US8580495B2 (en) 2002-11-12 2013-11-12 Abbott Laboratories Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
US9187789B2 (en) 2002-11-12 2015-11-17 Abbott Molecular Inc. Polynucleotides for the amplification and detection of chlamydia trachomatis and neisseria gonorrhoeae
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
US8790910B2 (en) 2006-07-25 2014-07-29 The Secretary Of State For Defence Live vaccine strain
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
US8609108B2 (en) 2009-04-14 2013-12-17 The Secretary Of State For Defence Gamma-glutamyl transpeptidase attenuated Francisella

Also Published As

Publication number Publication date
AU1411492A (en) 1992-09-07

Similar Documents

Publication Publication Date Title
US5834591A (en) Polypeptides and antibodies useful for the diagnosis and treatment of pathogenic neisseria and other microorganisms having type 4 pilin
US7700755B2 (en) Helicobacter pylori CAI antigen
EP0643770B1 (fr) Antigen immunodominant associe avec le cytotoxin d'helicobacter pylori utiles pour des vaccins et des diagnostics
CA2347849C (fr) Proteines omp85 de neisseria gonorrhoeae et de neisseria meningitidis, compositions renfermant lesdites proteines et methodes d'utilisation correspondantes
US7541181B2 (en) Vector carrying a polynucleotide which encodes a GSD polypeptide from Mycobacterium paratuberculosis
CA2224127C (fr) Gene de flagelline, flac de campylobacter
AU9598898A (en) Chlamydia protein, gene sequence and uses thereof
JPH09183791A (ja) Ｄｎａ断片
AU705998B2 (en) Haemophilus transferrin receptor genes
US7662588B2 (en) Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis, compositions containing same and methods of use thereof
WO1992013871A1 (fr) Polypeptides et polynucleotides utiles pour le diagnostic et le traitement de neisseria pathogene
US5874300A (en) Campylobacter jejuni antigens and methods for their production and use
US7192725B2 (en) Flagellin gene, flaC of Campylobacter
US6403306B1 (en) Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto
CA2223503C (fr) Genes du recepteur de la transferrine
US20070243204A1 (en) Helicobacter pylori proteins useful for vaccines and diagnostics
CA1338708C (fr) Vaccins a base de mutants de neisseria
US6130059A (en) Helicobacter pylori proteins useful for vaccines and diagnostics
EP1535928B1 (fr) Vaccin comprenant Omp85 protéines de Neisseria gonorhoeae et Neisseria meningitidis
WO1992016223A1 (fr) Production de proteines et vaccins pi gonorrheiques
CA2241023A1 (fr) Nouveaux polynucleotides et polypeptides dans des mycobacteries pathogenes et leur utilisation dans des diagnostics, des vaccins et des cibles de chimiotherapie
NZ502423A (en) Polynucleotide sequences, designated GS, in pathogenic mycobacteria and their use in vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/15-15/15,DRAWINGS,REPLACED BY NEW PAGES 1/35-35/35;DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载